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1.1. Hyaluronan 
1.1.1. Structure and physicochemical properties 
In 1934 Karl Meyer and his assistant John Palmer were the first to isolate hyaluronic acid 
from bovine vitreous humor; the name was composed of hyaloid (vitreous) and uronic 
acid, a component of the molecule (Meyer and Palmer, 1934). Nowadays, the nonsulfated 
glycosaminoglycan (GAG) is called hyaluronan, respecting the fact that the 
macromolecule exists as a polyanion in vivo, as the carboxyl groups of the glucuronic acid 
residues (pKa = 3 – 4) are predominantly charged (Hascall and Laurent, 1997). 
Hyaluronan was shown to be an acidic, negatively charged, linear polysaccharide 
consisting of long chains that are made up of disaccharide units comprising D-glucuronic 
acid and D-N-acetylglucosamine, linked by alternating ß-1,4 and ß-1,3 glycosidic bonds 
(Laurent and Fraser, 1992; Weissmann and Meyer, 1954) (Fig. 1.1).  
 
Fig. 1.1: The chemical structure of 
hyaluronan. The polysaccharide is made 
up of alternating units of glucuronic acid 
and N-acetylglucosamine. n= 2000 – 
25000. 
 
Usually, the polysaccharide consists of 2000 – 25000 disaccharide units, resulting in 
molecular masses from 10
6
 – 107 Da and lengths of 2 – 25 µm.  
In aqueous solution hyaluronan has been considered as a twofold helix, stabilized by 
internal hydrogen bonds (Atkins et al., 1980; Scott and Heatley, 2002). This conformation 
was hypothesized to be the basis of tertiary organization in solution. Recent structural work 
has led to a locally dynamic structure that is on average a contracted fourfold helix in 
aqueous solution (Almond et al., 2006).  
Dissolved hyaluronan chains have been shown to behave like typical semi-flexible 
polymer molecules (Cowman and Matsuoka, 2005). Therefore, hyaluronan is a space-
filling molecule that can undergo deformation as required during rapid growth and tissue 
remodeling. It can move unhindered into vacant spaces where it can keep cells stationary 
and give them a substrate on which to move (Almond, 2007).  
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1.1.2. Occurrence, synthesis and physiological roles 
Hyaluronan is present in all vertebrates and in the capsule of some strains of Streptococci. 
It is an essential component of the embryonic extracellular matrix in which cells 
differentiate and that of mature tissues (Hascall and Laurent, 1997). The highest concen-
trations of the polysaccharide are found in typical connective tissues e. g. in the skin (7 – 8 
g, ca. 50 % of the total hyaluronan in the body), the umbilical cord as well as a constituent 
of synovial fluid and the vitreous body, but notable amounts are also present in the lung, 
the heart valves, the kidney, the brain and in muscle (Fraser et al., 1997).  
Unlike other extracellular polysaccharides, synthesized in the Golgi apparatus, hyaluronan 
is produced on the inner face of the plasma membrane by hyaluronan synthases (HAS) and 
is extruded into the extracellular space. This simultaneous extrusion of the growing chain 
allows unconstrained polymer growth, thereby achieving the exceptionally large size of the 
molecule. Currently, three HAS isoforms have been identified in mammals (Weigel et al., 
1997) and there is evidence that the chain length depends on the individual HAS protein. 
While HAS1 and HAS2 catalyze the biosynthesis of chain lengths of up to 2 · 10
6
 Da, the 
product polymerized by HAS3 is significantly shorter (< 2 · 10
5
 – 1 · 106 Da) (Itano et al., 
1999). Hyaluronan chains of different lengths are supposed to exert various effects on cell 
behavior to be discussed later. 
Hyaluronan fulfills several physiological functions that contribute both, to structural tissue 
properties and to cell behavior during tissue formation and remodeling. Because of its 
hydrodynamic characteristics in terms of viscosity and the ability to retain water, it plays 
an important role in tissue homeostasis and biomechanical integrity. These properties form 
the basis of the widespread use of hyaluronan in tissue engineering (Allison and Grande-
Allen, 2006; Toole, 2004). The GAG also forms a multivalent template for interactions 
with proteoglycans and other extracellular molecules, which is important for the formation 
of the pericellular coat found for some cell types. During tissue formation and remodeling 
such matrices provide a hydrated fluid pericellular environment in which assembly of other 
matrix components and presentation of growth and differentiation factors can readily 
occur; without interference from the highly structured fibrous matrix usually found in fully 
differentiated tissues. In some cases, for instance in cartilage, the pericellular matrix is a 
unique structural component that protects cells and contributes to the characteristic 
properties of the differentiated tissue (Toole, 2001). Furthermore, hyaluronan interacts 
with cell surfaces and can mediate intracellular signals through binding to specific 
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receptors like CD44 or the receptor for hyaluronan mediated motility (RHAMM). The 
hyaluronan-binding receptors are described in the following section.  
In the early response to tissue injury, a temporary matrix rich in hyaluronan and fibrin is 
formed that supports the influx of fibroblasts and endothelial cells into the wound. The 
formation of granulation tissue is also supported (Oksala et al., 1995; Weigel et al., 1988; 
Weigel et al., 1986). Some studies showed that there is a beneficial effect of exogenous 
hyaluronan applied to chronic wounds (Ortonne, 1996; Vazquez et al., 2003), where tissue 
damage is one of the consequences of prolonged inflammation mediated by free oxygen 
radicals and matrix degrading enzymes. Therefore, the formation of granulation tissue is 
inhibited during these pathological conditions.  
Moreover, scarless fetal wound healing has been associated with a prolonged presence of 
high molecular weight hyaluronan, which led to the suggestions that the polysaccharide 
may inhibit fetal platelet function and reduce collagen deposition, precluding overshooting 
scar formation (Longaker et al., 1991; Olutoye et al., 1997).  
 
1.2. Hyaluronan receptors and signalling 
There are several cell surface receptors that have been identified for hyaluronan binding, 
namely CD44, RHAMM, the lymphatic vascular endothelial hyaluronan receptor (LYVE-
1), the toll-like receptor 4 (TLR-4) and the human hyaluronan receptor for endocytosis 
(HARE, also designated Stabilin-2). 
CD44, considered as the major receptor for hyaluronan, comprises a group of 
multifunctional type-I transmembrane glycoproteins, which are all encoded by a highly 
conserved gene. The heterogeneity of the gene products is due to alternative splicing of 
multiple variant exons and is in part generated by post-translational modifications (Ponta et 
al., 2003). All CD44 isoforms contain a hyaluronan-binding site on the link module in their 
extracellular domain, but binding properties are determined by the isoform and the cell 
type on which it is expressed (Day and Prestwich, 2002). Through interaction of the 
intracellular domain of CD44 with cytoskeletal proteins and specific signaling, there is an 
association between hyaluronan binding and cell behavior (Bourguignon et al., 1998). For 
example, hyaluronan–CD44 interactions contribute to cell–cell aggregation, matrix–cell 
and cell–matrix signaling, receptor-mediated degradation/internalization of hyaluronan and 
retention of the pericellular matrix (Girish and Kemparaju, 2007). Upon hyaluronan 
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binding the cytoplasmatic domain of CD44 binds to c-Src kinase, which leads to increasing 
tyrosine phosphorylation of the cytoskeletal protein cortactin which in turn attenuates 
cross-linking of filamentous actin in vitro (Bourguignon et al., 2001). Moreover, CD44 
interacts with the membrane linker proteins ezrin/radixin/moesin (ERM) and another 
member of the membrane-associated cytoskeletal protein family, ankyrin, which promotes 
hyaluronan-dependent and CD44-specific tumor cell migration (Turley et al., 2002). 
RHAMM is also alternatively spliced and is distributed to multiple compartments 
(mitochondria and the cell nucleus) as well as to the cell surface and to the cytoskeleton. 
This receptor has been shown to promote cell motility via different pathways. The binding 
of hyaluronan to RHAMM on the cell surface mediates transient activation of c-Src, focal 
adhesion kinase (FAK) , the MAP kinases Erk-1 and -2 and protein kinase C (Hall et al., 
1994; Turley et al., 2002). Furthermore, hyaluronan-induced increase in cell motility is 
accompanied by a rapid formation and then disassembly of focal adhesions and spreading 
of cell lamellae, which is also mediated by binding to cell-surface RHAMM (Hall et al., 
1994). 
Like CD44, LYVE-1 is a member of the link protein superfamily and is expressed in 
lymphatic vessels. The role of this receptor has not been elucidated so far. It has been 
speculated about its involvement in the uptake of hyaluronan for its catabolism or in cell 
adhesion, either in promoting or blocking the interaction of leukocytes with the 
endothelium (Jackson, 2004). 
Hyaluronan oligosaccharides induce maturation of dentritic cells (DC) via the TLR-4 
pathway, where phosphorylation of MAP-kinases and the nuclear translocation of NF-κB 
take place. TLRs belong to the IL-1 receptor family and participate in the innate defense 
against bacterial infection through activation of immunocompetent cells like macrophages 
and DCs (Termeer et al., 2002). 
HARE exists in two isoforms and mediates the endocytotic clearance of hyaluronan and 
other GAGs from lymph and blood. It is highly expressed by the sinusoidal cells of the 
liver and the endothelial cells of the spleen and the lymph nodes (Zhou et al., 2000). 
Hyaluronan bound to HARE is internalized and degraded in lysosomes, completing the 
physiological turnover process described in the next section. 
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1.3. Hyaluronan turnover 
1.3.1. Hyaluronidases 
Hyaluronidases are enzymes that degrade hyaluronan for catabolism; to produce small 
fragments with signaling character or in case of venoms and bacterial hyaluronidases they 
serve as spreading factor to facilitate distribution in the host. Hyaluronidases have been 
identified in a number of organisms, such as mammals, bacteria and pathogenic fungi (e. g. 
Candida) and in the venom of snakes, lizards and insects (e. g. bee venom hyaluronidase). 
The isolated enzymes differ in their substrate specificity, pH optimum and their catalytic 
mechanism of hyaluronan degradation (Csoka et al., 1997b; Frost et al., 1996; Meyer, 
1971). 
 
1.3.1.1. Bacterial hyaluronidases 
Many pathogenic bacteria produce hyaluronidases (hyaluronate lyases), which serve as 
virulence factors. Since hyaluronan is a major constituent of the ground substance of most 
connective tissues, hyaluronidase may be an essential factor in enabling the spread of the 
pathogens from an initial site of infection. Moreover, the end products of hyaluronan 
degradation are disaccharides, which may be internalized and metabolized to supply 
nutrients for the bacterium (Hynes and Walton, 2000).  
The best known and characterized bacterial hyaluronate lyases are those from 
Streptococcus agalactiae and Streptococcus pneumoniae, respectively. The degradative 
process of both enzymes is thought to proceed via a sequential mode initialized by a 
random cut in the hyaluronan chain. Subsequently, degradation precedes toward the 
nonreducing end until the whole substrate is degraded by a ß-elimination reaction, 
resulting in the unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(ß-D-gluco-4-ene-
pyranosyluronic acid)-D-glucose (ΔDiHA) (Li et al., 2000; Pritchard et al., 1994) (Fig. 
1.2). 
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Fig. 1.2: Cleavage of hyaluronan to unsaturated disaccharides by hyaluronate lyase. Red arrows 
mark bonds which are cleaved. 
 
1.3.1.2. Human Hyaluronidases 
There are six hyaluronidase-like sequences with about 40 % identity to each other encoded 
in the human genome. Those of HYAL1, HYAL2 and HYAL3 are clustered on 
chromosome 3p21.3, the other three genes encoding HYAL4, PH-20 and HYALP1 on 
chromosome 7q31.3 (Csoka et al., 2001).  
Hyaluronidase-1 (Hyal-1) was first isolated from human plasma and is the predominant 
hyaluronidase in human plasma and urine. It has also been found at high levels in the 
kidney, liver, spleen and heart. The enzyme is localized in lysosomes and works at acidic 
pH (Csoka et al., 1997a; Frost et al., 1997). In addition to its function in normal hyaluronan 
turnover, Hyal-1 is implicated in cancer cell proliferation, angiogenesis and inflammation. 
For example, the expression of the enzyme is up-regulated in high grade bladder and 
prostate cancers (Lokeshwar et al., 2000; Lokeshwar et al., 2001). Presumably, Hyal-1 
degrades hyaluronan into angiogenic fragments (see 1.4), which might promote the growth 
of hyaluronidase overexpressing cancer types. Furthermore, the hereditary disease 
mucopolysaccharidosis IX, a lysosomal storage disorder, has been associated with 
inactivating mutations of Hyal-1 (Triggs-Raine et al., 1999).  
Besides Hyal-1, hyaluronidase-2 (Hyal-2) is one of the major hyaluronidases in somatic 
tissues. Hyal-2 has been proposed to act in concert with Hyal-1 in the catabolism of 
hyaluronan (Stern, 2004), but its enzymatic activity is a matter of controversial discussion, 
further described in Chapter 3. 
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Hyaluronidase-3 (Hyal-3) is still a mystery. It is expressed in several tissues, especially in 
testis and bone marrow (Csoka et al., 1999), but until now, its enzymatic activity or 
physiological relevance are totally unclear. Recently, a possible role in fertilization was 
suggested, as Hyal-3 may contribute to acidic hyaluronidase activity in mouse sperm 
(Reese et al., 2010). 
Hyaluronidase-4 was shown to display only chondroitinase, not hyaluronidase activity 
(Kaneiwa et al., 2010). 
PH-20, also known as SPAM 1 (spam adhesion molecule 1) is located on the membrane, 
bound to a GPI-anchor and in the lysosome-derived acrosome of mammalian sperm and 
plays an important role during fertilization. It degrades the hyaluronan-enriched cumulus 
of the oocyte during sperm penetration and then serves as receptor for the sperm binding to 
the zona pellucida inducing hyaluronan-associated sperm signaling (Cherr et al., 2001; Lin 
et al., 1994; Primakoff et al., 1985). Membrane-bound PH-20 shows hyaluronidase activity 
only at neutral pH, whereas acrosomal PH-20 was found to be active at both acidic and 
neutral pH. These different activities appear to involve two different domains of the 
protein; acidic hyaluronidase activity may be evoked after the acrosome reaction, where 
the enzyme is endoproteolytically cleaved, but held together by a disulfide bond. This 
cleavage may alter the three-dimensional structure of PH-20 resulting in an activation of 
the domain responsible for activity at acidic pH (Cherr et al., 2001). 
HYALP1 is a pseudogene and does not encode for an active enzyme in humans. 
 
1.3.2. Model of hyaluronan turnover 
It is estimated that 5 g out of 15 g of hyaluronan in a 70 kg individual are replaced daily. 
Turnover rates vary widely between tissues; the half-life of the macromolecule is about 1 
day in the skin and 1–3 weeks in relatively inert cartilage (Stern, 2003). In the blood 
stream, the turnover of hyaluronan is very rapid with a half life of 2–5 min (Fraser et al., 
1981). 
However, the catabolic pathways responsible for the clearance of hyaluronan have not 
been elucidated completely until now. CD44 is known to bind hyaluronan and it is also 
thought to contribute to internalization of the polysaccharide (Culty et al., 1992; Hua et al., 
1993; Kaya et al., 1997), but the molecular mechanisms of endocytosis are largely 
unknown. However, it is likely that high molecular weight hyaluronan is tethered to the 
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cell surface by CD44 and that it is degraded by membrane-bound Hyal-2 to a certain 
extent. This could take place in specialized microdomains, so-called caveolae. The 
truncated hyaluronan chains may then be internalized, delivered to endosomes and 
ultimately to lysosomes, where they are degraded by Hyal-1, and the lysosomal 
exoglycosidases ß-glucuronidase and ß-N-acetylglucosaminidase to the final catabolism 
products (Stern, 2004). The possible metabolic scheme is depicted in Fig. 1.3. 
 
Fig. 1.3: Possible metabolic scheme of hyaluronan degradation through concerted action of CD44, 
Hyal-2 and Hyal-1. Modified from Csoka et al. (2001).  
 
1.4. Size-dependent functions of hyaluronan fragments 
Hyaluronan chains of different lengths resulting from HAS-catalyzed synthesis and 
degradation by hyaluronidase, respectively, show very different biological functions. High 
(HMW) and low (LMW) molecular weight chains seem to have opposing cellular effects. 
The extracellular HMW polysaccharides inhibit angiogenesis (Feinberg and Beebe, 1983) 
and also show anti-inflammatory and immune-suppressive effects (Delmage et al., 1986; 
McBride and Bard, 1979). LMW hyaluronan fragments are involved in a number of 
physiological and pathophysiological processes, like induction of inflammatory cytokines, 
angiogenesis and tumor cell migration. During the inflammatory stage of wound healing, 
LMW hyaluronan, having a polydisperse mass distribution with an average around 2.5 · 
10
5
 Da, accumulates and induces the expression of inflammatory cytokines in monocytes, 
such as macrophage inflammatory protein 1 alpha (MIP-1 alpha), MIP-1 beta, IL-12, IL-1 
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beta, tumor necrosis factor alpha (TNF-α) and insulin-like growth factor-1 (IGF-1) 
(Hodge-Dufour et al., 1997; Horton et al., 1998; Noble et al., 1993). Moreover, LMW 
fragments with a size of 8–32 disaccharide units were shown to stimulate angiogenesis by 
enhancing endothelial cell migration and induction of multiple signaling pathways (Sattar 
et al., 1994; Slevin et al., 2002). LMW hyaluronan fragments are also found in cancers, 
where tumor cell motility and invasion are facilitated. For example, highly invasive 
bladder cancers produce angiogenic hyaluronan fragments, which may contribute to the 
invasiveness (Stern et al., 2006). 
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Hyaluronan and its catabolic products are increasingly gaining attention with respect to 
embryonic development, cell biology, oncology and immunology. For a more detailed 
insight into the pathways of hyaluronan catabolism, the enzymological characterization of 
the individual hyaluronidases is a prerequisite. Particularly, the enzymatic activity of 
hyaluronidase-2 is still a matter of controversial discussion. Recently, hyaluronidases 1 and 
2 were suggested to be the major hyaluronidases in somatic tissues and to act in concert in 
the degradation of hyaluronan. However, supposed that Hyal-2 plays a crucial role in the 
turnover of hyaluronan, enzymatic activity is a prerequisite. Therefore, the major goal of 
this thesis was to prove that Hyal-2 is a catalytically active protein, and to explore its 
biological role in platelets and red blood cells. 
The first part of this thesis aimed at the investigation of the enzymatic activity of Hyal-2, 
using a purified recombinant enzyme expressed in insect cells, and native enzyme 
expressed by blood platelets and red blood cells. Viscosimetry was previously shown to be 
the most sensitive method to show hyaluronan degrading activity, compared to other 
conventional hyaluronidase assays, such as turbidimetry and the Morgan-Elson reaction. 
Additionally, an electrophoretic method had to be established and optimized to allow the 
determination of the size distribution of possibly formed hyaluronan fragments. Moreover, 
proliferation studies with human endothelial cells were intended in order to investigate, if 
Hyal-2 is able to produce signalling hyaluronan fragments. 
The design and synthesis of hyaluronidase inhibitors is subject of several doctoral projects 
pursued in parallel with the present work. Hyaluronidases represent a heterogeneous group 
of enzymes of different origin. For example, pathogenic strains of Streptococci produce 
hyaluronate lyases, which have been suggested virulence factors. S. pneumoniae, a 
bacterial respiratory pathogen, produces such a hyaluronate lyase (SpnHyl). Hence, another 
goal of this thesis was to find drug-like small molecules as lead structures of inhibitors of 
SpnHyl, which might be useful as adjuvants in antibiotic therapy. 
Consequently, a library of small molecules, prepared by multicomponent reactions, was 
provided by Christian Textor, to be screened in a turbidimetric assay in order to investigate 
inhibitory activities on SpnHyl. For this purpose, the enzyme had to be expressed in E. coli 
strain BL21 (DE 3).  
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3.1. Introduction 
The m-RNA of Hyaluronidase-2 (Hyal-2), also termed LUCA-2, has been found in many 
somatic tissues except the adult brain. It was initially described as an enzyme, which is 
active at acidic pH and located in lysosomes (Lepperdinger et al., 1998). However, Hyal-2 
is still not characterized very well and the few publications dealing with its localization and 
activity have been rather contradictory. 
Several authors published that Hyal-2 is a protein, which is bound to the cell membrane via 
a glycosylphosphatidylinositol (GPI) anchor (Miller, 2003; Mullegger and Lepperdinger, 
2002; Rai et al., 2001). In other publications a lysosomal localization is proposed (Chow et 
al., 2006a, b; Lepperdinger et al., 1998). To explain the different findings, Chow et al. 
speculated about a primary localization of Hyal-2 in lysosomes with a fraction being 
transferred to the cell membrane (Chow et al., 2006b), whereas Lepperdinger et al. 
suggested that Hyal-2 is transported to lysosomes via secretion and re-uptake at the plasma 
membrane (Lepperdinger et al., 2001). 
The comparison of publications regarding catalytic activity of Hyal-2 raises even more 
questions. Lepperdinger et al. were the first who reported that Hyal-2 is enzymatically 
active at pH 3.8 and that substrate degradation stops with fragments of a molecular weight 
of approximately 20 kDa (Lepperdinger et al., 1998). Thereby, Hyal-2 was expressed by 
means of a recombinant vaccinia virus containing human Hyal-2 cDNA in C6 glioma cells. 
By contrast, Rai et al. could not detect any hyaluronidase activity using HEK293 cells 
transfected with human Hyal-2 (Rai et al., 2001). Moreover, Vigdorovich et al. 
investigated a soluble form of Hyal-2 (sHyal-2) and reported on enzymatic activity at a 
broad pH range from 4.5 – 8.6 (Vigdorovich et al., 2005). However, this activity was found 
to be due to a contaminating hyaluronidase present in the used expression system. A re-
investigation with purified sHyal-2 revealed little hyaluronidase activity at pH 5.6 
(Vigdorovich et al., 2007). 
Hyal-2 has been supposed to have different physiological roles. It serves as cell entry 
receptor for the Jaagsiekte sheep retro virus (JSRV) (Miller, 2003; Rai et al., 2001) and is 
therefore responsible for the strong oncogenic potential of the retrovirus. Furthermore, this 
hyaluronidase has been proposed to act in concert with Hyal-1 in the catabolism of 
hyaluronan in the ECM (Csoka et al., 2001). It also plays a role in HA fragmentation in the 
airway lumen in inflammatory conditions associated with oxidative stress (Monzon et al.). 
Aside from these functions, Duterme et al. found a relation between Hyal-2 expression and 
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the formation of the glycocalyx and a regulation of CD44-ERM interactions by Hyal-2 
(Duterme et al., 2009). 
E. Hofinger transfected Drosophila Schneider-2 cells (DS-2) with His-tagged recombinant 
human Hyal-2 (rhHyal-2) (Hofinger, 2007). DS-2 cells are a suitable expression system for 
hyaluronidases because of the absence of hyaluronan (Toyoda et al., 2000) and 
hyaluronidase-like genes. By these stably transfected DS-2 cells rhHyal-2 was excreted 
into the medium as a soluble protein and purified by Ni-IMAC or a simplified purification 
protocol. In this work, purified Hyal-2 was characterized with respect to catalytic activity 
and supplied to a cooperation partner for antibody production. 
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3.2. Materials and methods 
3.2.1. Cultivation and storage of stably transfected DS-2/pMTHygro/Hyal-2 cells 
DS-2/pMTHygro/Hyal-2 cells were grown in serum-free Insect-XPRESS™ medium 
(Lonza Cologne AG, Cologne, Germany) containing 300 µg/mL hygromycin B (A.G. 
Scientific Inc., San Diego, USA) at 27 °C. For sub-culturing, adherent cells were grown in 
25-cm² culture flasks (Sarstedt, Nürnbrecht, Germany) and serially passaged every 4 – 5 
days. Confluent cells were removed from the bottom of the culture flask by tapping, and 
the suspension was diluted 5 – 6 fold with fresh medium.  
For long term storage, cells were grown to a density of 1 – 2 · 107 cells per mL and 
centrifuged at 1000 g for 3 min at 4 °C. Cells were re-suspended in the same volume of 
sterile PBS and centrifuged again. After re-suspension in the same volume of freezing 
medium (45 % fresh medium, 45 % conditioned medium, 10 % DMSO), the cell 
suspension was split into aliquots of 1 mL and cooled down slowly for the storage in liquid 
nitrogen. For revival an aliquot of frozen cells was quickly thawed and diluted 5 – 6 fold 
with fresh medium. After attachment of the cells to the bottom of the culture flask, medium 
was exchanged with fresh medium to remove residual DMSO. 
 
3.2.2. Expression of rhHyal-2 in DS-2 cells 
For expression of His-tagged rhHyal-2, suspension cultures with initially 1 – 2 · 106 of DS-
2/pMTHygro/Hyal-2 cells per mL in Insect-XPRESS™ medium supplemented with 300 
µg/mL hygromycin were used and shaken at 135 rpm at 27 °C for 10 days. Cells were then 
harvested by centrifugation at 1500 g for 15 min at 4 °C. The medium was used for 
isolation of rhHyal-2. 
 
3.2.3. Isolation and purification of rhHyal-2 by Ni-IMAC 
Imidazole and triton X-100 were added to the collected rhHyal-2 containing cell culture 
medium at a final concentration of 20 mM and 0.1 %, respectively, and the pH was 
carefully adjusted to 7.4. After the solution was clarified by centrifugation at 8000 g for 30 
min at 4 °C, the sample was loaded onto a HisTrap™ HP Ni-IMAC column (column 
volume (CV) 5 mL, GE Healthcare, Munich, Germany). Before loading the sample, the 
column was equilibrated with binding buffer (20 mM Na2HPO4, 0.5 M NaCl, 20 mM 
imidazole, 0.1 % Triton X-100, pH 7.4). After washing with 15 CV of binding buffer, the 
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immobilized His-tagged Protein was eluted with 10 CV of elution buffer (20 mM 
Na2HPO4, 0.5 M NaCl, 0.5 M imidazole, 0.1 % triton X-100, pH 7.4). Protein purification 
was performed with an ÄKTA FPLC device with a Frac-950 fraction collector using 
UNICORN™ v5.10 software (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) at a 
flow rate of 5 mL/min and a pressure limit of 0.3 MPa. The chromatography was 
monitored by UV detection at 280 nm. The protein content of the collected elution 
fractions (6 mL) was determined using the BCA assay and plotted against the respective 
elution volume. Then, the elution fractions were pooled, dialyzed against 0.1 M 
ammonium acetate and lyophilized. 
 
3.2.4. Bicinchoninic acid (BCA) protein assay 
For the determination of the protein content using the BCA assay, three stock solutions 
were prepared. Reagent A: 4.0 g Na2CO3, 0.8 g NaOH and 0.08 g K-Na-tartrate were 
dissolved in 50 mL of water and the pH was adjusted to 11.25; reagent B: 1.0 g of BCA 
was dissolved in 25 mL of water; reagent C: 4 % CuSO4 x 5 H2O in water. For preparation 
of the working solution 1 volume of reagent C was mixed with 25 volumes of reagent B 
and 26 volumes of reagent C. A BSA standard curve from 5 – 200 µg/mL was prepared 
from a 1 mg/mL stock solution (BSA in elution buffer). 70 µL of working solution were 
added to 70 µL of sample or standard and incubated in a 96-well microtiter plate for 1 h at 
60 °C. After cooling, the absorbance at 540 nm was measured using a Tecan Genios Pro 
microtiter plate reader (Tecan, Crailsheim, Germany) with XFluor Genios Pro software 
version V.4.55. The standard curve was plotted as absorbance versus µg/mL of BSA and 
the protein concentration of the samples was determined. 
 
3.2.5. Simplified purification protocol for rhHyal-2 
To simplify the purification procedure, Ni Sepharose™ 6 FF (GE Healthcare, Munich, 
Germany) was used and the purification was performed according to the manufacturer´s 
instructions for gravity-flow purification with minimal changes. In brief, 2 mL of Ni 
Sepharose slurry were sedimented by centrifugation at 1000 g for 3 min and then washed 
with 5 mL of Millipore water. After gentle shaking for 30 min and centrifugation, the 
water was discarded and replaced with 5 mL of binding buffer (20 mM Na2HPO4, 0.5 M 
NaCl, 20 mM imidazole, pH 7.4). The shaking and centrifugation procedure was repeated, 
subsequently a 50 % slurry of Ni Sepharose and binding buffer was made and allowed to 
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equilibrate for 5 min. 4 mL of clarified DS-2/pMTHygro/Hyal-2 medium, containing 20 
mM imidazole were added per mL of slurry and the resulting loading suspension was 
gently shaken for 1 h at RT. The incubated loading suspension was transferred to empty 
gravity flow columns and washed 3 times with 2 mL of binding buffer. Bound protein was 
detached from the chromatography material with 2 mL  of elution buffer (20 mM 
Na2HPO4, 0.5 M NaCl, 0.5 M imidazole) added in four 0.5 mL portions. A buffer 
exchange of the elution fractions was achieved with PD-10 columns (Sigma-Aldrich, 
Munich, Germany) using 0.1 M ammonium acetate. Samples were lyophilized, and their 
protein content was determined. Purity of the received protein was controlled by SDS-
PAGE. 
 
3.2.6. SDS-Polyacrylamide gel electrophoresis 
Proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) under reducing conditions. The composition of all required buffers is 
summarized in Tab. 3.1. 12 % polyacrylamide separating gels contained 2.2 mL of water, 
2 mL of buffer A and 3.2 mL of acrylamide/bisacrylamide 30 % solution 
(acrylamide/bisacrylamide 29/1; Sigma-Aldrich, Munich, Germany). Polymerization was 
initiated by adding 3.5 µL N,N,N′,N′-tetramethylethylenediamine (TEMED, Serva, 
Heidelberg, Germany) and 35 µL of ammonium peroxodisulfate (APS, 10 % solution in 
water, Serva, Heidelberg, Germany). The mixture was filled into gel chambers (10 x 10 x 
0.8 cm) and overlaid with water saturated isobutyl alcohol. After complete polymerization, 
the isobutyl alcohol layer was discarded and a 5 % stacking gel was casted. The stacking 
gel contained 3.25 mL of water, 1.25 mL of buffer B and 0.5 mL of 
acrylamide/bisacrylamide 30 % solution. 3.5 µL of TEMED and 50 µL of APS were added 
to start polymerization. Electrophoresis was performed in a PerfectBlue gel electrophoresis 
system Twin S (Peqlab, Erlangen, Germany) with the electrode chambers filled with 1 x 
running buffer at 150 V for approximately 2 h. Protein samples were mixed with a one-
third volume of sample buffer and heated for 5 min at 100 °C. 
Tab. 3.1: Composition of buffers for SDS-PAGE. 
Buffer and 
additives 
Buffer A Buffer B 
Running buffer 
10 x 
Sample buffer 
Tris (M) 1.5 0.5 0.25 0.075 
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Glycin (M) - - 2 0.5 
SDS (%, m/v) 0.4 0.4 1 0.3 
Glycerol (%, 
v/v) 
- - - 4.5 
Bromophenol 
blue (%, m/v) 
- - - 0.05 
Mercaptoethanol 
(%, v/v) 
- - - 1 
pH 8.8 6.8 8.3 6.8 
 
3.2.7. Western Blot analysis 
After SDS-PAGE, the proteins were transferred to a nitrocellulose membrane (0.2 µm, 
Peqlab, Erlangen, Germany) in a PerfectBlue “Semi-Dry” electro blot apparatus (Peqlab, 
Erlangen, Germany). The gel was equilibrated in transfer buffer (186 mM glycine, 25 mM 
tris, 20 % (v/v) methanol), placed on top of the membrane between 6 filter slides soaked in 
transfer buffer and blotted for 45 min at 2.5 mA/cm
2
. The membrane was subsequently 
blocked by washing with 5 % (w/v) fat-free milk-powder dissolved in a mixture of 1 x tris 
buffered saline (10 x buffer: 1.4 M NaCl, 0.2 M tris, pH 7.6) and 0.1 % tween-20 (v/v) 
(TBST) for 2 h at room temperature. After washing with TBST three times for 5 min, the 
primary antibody (anti-Hyal-2 from Abcam, Cambridge, UK) diluted 1000-fold in 25 mL 
of TBST was incubated overnight at 4 °C with the membrane. After washing, the 
secondary antibody (donkey anti-rabbit IgG-HRP from Santa Cruz Biotechnology, Santa 
Cruz, USA), diluted 10000-fold in 25 mL of TBST, was added and shaken with the 
membrane at RT for 1 h. Immunoreactive bands were visualized by enhanced 
chemiluminescence with the Pierce
®
 ECL detection kit (Thermo Fisher scientific, Bonn, 
Germany) according to the manufacturer´s instructions. Blots and gels were analyzed in a 
Bio-Rad gel detection system (GS-710 Imaging Densitometer) using Quantity One 
quantification software, version 4.0.3. (Bio-Rad, Munich, Germany). 
 
3.2.8. Viscosimetric hyaluronidase activity assay 
The decrease in viscosity of the substrate solution was determined in a micro Ubbelohde 
capilllary viscosimeter (Schott Instruments, Mainz, Germany). The viscosimeter was 
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clamped into an AVS measurement tripod connected to an AVS automated measuring 
device (Schott Instruments, Mainz, Germany). Sample mixtures containing 1 mL of 
McIlvaine´s buffer (pH 4.0), 1 mL of BSA (0.2 mg/mL), 3 mL of HA-solution (5 mg/mL) 
and 1 mL of sample solution were incubated at 37 °C for 24 – 96 h and viscosity was 
measured at various time points. Due to the negligibly short time of viscosity measurement 
compared with the long time period required for the incubation of the substrate with the 
enzyme, outflow times were not added to incubation periods. 
The relative viscosities ηrel were calculated according to the following equations: 
     
 
    
 
   
      
 
      
        
 
Eq.  3.1 
with ν being the kinematic viscosity of the sample and νref that of the reference. K is the 
viscosimeter constant (0.03126 mm
2
/s
2
). The outflow time tM, measured for the sample and 
tref for the reference were both corrected by the Hagen-Couette correction time (tHC) 
according to the manufacturer´s recommendation. References were prepared by replacing 
HA with H2O in the sample mixture. 
To compare changes in viscosity, ηrel (%) was plotted versus incubation time. ηrel (%) was 
calculated according to the following equation: 
         
        
        
     
Eq. 3.2 
with ηrel (tn) and ηrel (t0) being the relative viscosities at time point n and at the beginning of 
the incubation period, respectively. 
 
3.2.9. Polyacrylamide gel electrophoresis followed by combined alcian blue silver 
staining 
Polyacrylamide gel electrophoresis was performed by analogy with a previously described 
protocol (Ikegami-Kawai and Takahashi, 2002; Min and Cowman, 1986). 10 % 
polyacrylamide gels contained 5 mL of tris/borate/EDTA (TBE) buffer (89 mM tris; 82 
mM boric acid; 2 mM EDTA, pH 8.3) and 2.5 mL of acrylamide/bisacrylamide 30 % 
solution. Polymerization was started by adding 3.5 µL of TEMED and 35 µL of 10 % 
APS. The mixture was filled into gel chambers (10 x 10 x 0.8 cm) and overlaid with water 
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saturated isobutyl alcohol. After complete polymerization, the isobutyl alcohol layer was 
discarded and a 5 % stacking gel was casted. The stacking gel contained 4.1 mL of TBE 
buffer and 0.85 mL of acrylamide/bisacrylamide 30 % solution. Polymerization was again 
initiated with 3.5 µL of TEMED and 35 µL of 10 % APS. Hyaluronan digest samples and 
sulphonated polystyrenes in water, respectively, were mixed with a one-fifth volume of 2 
M sucrose in TBE buffer and 2 µL thereof were applied directly to the gel. Bromophenol 
blue (BPB) was used as a tracking dye. For electrophoresis, the electrode chambers were 
filled with TBE buffer and the gels were run first at 250 V for 20 min, then at 500 V for 10 
min, and, additionally, at 400 V for approximately 15 min until the BPB tracking dye 
reached the gel bottom. After electrophoresis, a combined alcian blue and silver staining 
protocol was used for the detection of oligosaccharides, similar to that of Ikegami-Kawai 
and Takahashi (Ikegami-Kawai and Takahashi, 2002). Firstly the gel was soaked in alcian-
blue solution (0.5 % alcian-blue in 2 % acetic acid) for 30 min and under light protection. 
Afterwards, destaining was achieved by shaking in 2 % acetic acid for 30 min. The 
subsequent silver staining protocol was performed according to Merril et al (Merril et al., 
1981). In brief: after destaining the gel was soaked in oxidation solution (3.4 mM K2Cr2O7, 
3.2 mM HNO3) for 5 min and then it was washed for 3 x 5 min in water before putting the 
gel in 12 mM AgNO3 solution for another 20 min. Then, the gel was washed in water for 3 
min and soaked in developing solution (5 g Na2CO3, 100 µL of formaldehyde in 200 mL of 
water) until bands of appropriate intensity became visible. Development was stopped by 
soaking the gel in 5 % acetic acid for 15 min. Gels were stored in water until they were 
analyzed. 
 
3.3. Results and discussion 
3.3.1. Purification of rhHyal-2 from DS-2 cell medium 
The medium from rhHyal-2 expression was first purified using Ni-IMAC. The purity of the 
lyophilized elution fractions was sufficiently high, though the yield of the protein was very 
low. Fig. 3.1 A shows a typical profile of the FPLC purification, the protein content of the 
elution fractions was plotted against the respective elution volume. SDS-PAGE of 5 µg of 
the purified, lyophilized protein revealed a protein band with a molecular mass of 54 kDa, 
which is consistent with the calculated mass of Hyal-2. Another band with a molecular 
mass of 40 kDa was detected, which represents either non-glycosylated Hyal-2, or it may 
be speculated about an artefactual protein degradation product, originated from sample 
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preparation (Cookson and Beynon, 1987). The former protein was identified as rhHyal-2 
by Western Blot analysis, showing an immunoreactive band at approximately 60 kDa (Fig. 
3.1, B). 
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Fig. 3.1: A: Elution profile of rhHyal-2 purification using Ni-IMAC, protein content of the elution 
fractions was plotted against the respective elution volume; B: silver stained SDS-PAGE (left) and 
Western Blot analysis (right) of 5 µg of purified, lyophilized rhHyal-2. A polyclonal anti-Hyal-2 
antibody was used as primary antibody, HRP-conjugated anti-rabbit-IgG as secondary antibody and 
detection was achieved by ECL. 
 
3.3.2. Purification of rhHyal-2 according to a simplified protocol using Ni 
Sepharose™ 6 FF 
As the protein content after FPLC purification was rather low and the protein containing 
elution fractions had been pooled anyway, a simplified and faster method for purification 
was used. This procedure gave similar qualitative results to the chromatographic 
purification. Silver stained SDS-PAGE of 5 µg lyophilized protein showed two bands with 
molecular weights of 54 and 42 kDa, respectively. Identification as rhHyal-2 was again 
achieved by Western Blot analysis, which revealed two immunoreactive bands with 
molecular weights of approximately 60 and 45 kDa, respectively (Fig. 3.2). The rhHyal-2 
was still very low, but neither a longer expression time, nor thawing of another batch of 
transfected cells increased the protein yield. 
A
> 
B
> 
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Fig. 3.2: SDS-PAGE (left) and Western Blot 
analysis (right) of purified, lyophilized rhHyal-
2. Gels were loaded with 5 µg of protein and 
silver stained. Immunoreactive bands were 
visualized by ECL. 
 
A total amount of 430 µg of purified, lyophilized rhHyal-2 was obtained, from which 200 
µg were sent to our collaboration partners in Namur, Belgium for monoclonal antibody 
production. Moreover, obtained rhHyal-2 was characterized with respect to hyaluronan 
degrading activity. 
 
3.3.3. Determination of enzymatic activity of purified rhHyal-2 by viscosimetry 
Hyaluronidase activity, if any, of the purified protein was expected to be rather low. For 
this reason, viscosimetry, the most sensitive method of the classical hyaluronidase assays 
with a limit of quantitation of 0.1 IE/mL (bovine testicular hyaluronidase, hyaluronan from 
S. zooepidemicus, 37 °C, period of incubation: 24 h) was used for the investigations. For 
comparison, the limits of quantitation for the Morgan-Elson and the turbidity assay at the 
same conditions were 2 IE/mL and 5 IE/mL, respectively (Hofinger, 2007). 
Viscosimetric measurements were performed at pH 4 as acidic conditions were used in the 
majority of studies suggesting Hyal-2 to be an enzymatically active protein. Dependency 
of Hyal-2 activity on pH is described in the next chapter. Decrease in viscosity was 
compared to that triggered by rhHyal-1 (Hofinger et al., 2007) and to incubation mixture 
without enzyme, respectively. Error bars presented in Fig. 3.3 are SEM of three 
independent experiments.  
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Fig. 3.3: Viscosimetric analysis of enzymatic activity of purified lyophilized rhHyal-2. Incubation 
of HA (circles) with rhHyal-2 (squares), compared to rhHyal-1 (triangles) using hyaluronan from 
different sources. A: HA from S. zooepidemicus; B: HA from human umbilical cord. 
The viscosimetric analyses revealed that purified, lyophilized rhHyal-2 is able to degrade 
hyaluronan. The viscosity of the control slightly decreased over time. This can be 
explained by degradation of hyaluronan by reactive oxygen species (Soltes et al., 2006), 
which can be present in the environment during the long incubation time needed. By 
contrast, there was a pronounced decrease in viscosity of samples containing rhHyal-2.  
Strikingly, the enzymatic activity depended on the source of hyaluronan used in the assay. 
Hyaluronan from human umbilical cord (Fig. 3.3 B) was degraded faster and apparently to 
a higher extent than hyaluronan from S. zooepidemicus (Fig. 3.3 A). As described 
previously, HA from human umbilical cord possesses shorter chain lengths than the 
bacterial HA (Hoechstetter, 2005). Possibly, the activity of rhHyal-2 is hampered by the 
formation of secondary and tertiary structures of HA through intramolecular interactions, 
which would be facilitated with increasing chain length, decreasing the probability of an 
endolytic attack at the hyaluronan from S. zooepidemicus. 
 
A B 
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3.3.4. Determination of enzymatic activity of rhHyal-2 by electrophoresis 
In order to verify the results of the viscosimetric analyses and to get a hint regarding the 
HA fragment size distribution resulting from Hyal-2 activity, electrophoretic investigations 
were performed. For this purpose, rhHyal-2 mediated hyaluronan degradation was 
compared with the action of rhHyal-1, and the approximate size of the generated fragments 
was determined by comparing the migration of the fragments with these of different 
sulphated polystyrenes of known average molecular mass. 
The electrophoresis was performed after viscosimetry using both types of hyaluronan as 
substrates to substantiate the differences in the degradation pattern. In Fig. 3.4 lanes of a 
PAA gel electrophoresis loaded with hyaluronidase incubation mixtures (HA from S. 
zooepidemicus) is shown. Degradation catalyzed by rhHyal-2 stops at chain lengths of 
about 20 kDa as already described by Lepperdinger et al. (Lepperdinger et al., 1998). 
 
Fig. 3.4: Polyacrylamide gel electrophoresis and corresponding densitometric scans of HA derived 
from S. zooepidemicus (lane A) incubated with 20 µg lyophilized rhHyal-2 for 48 h (lane B) and 
0.0042 U/mL rhHyal-1 for 24 h (lane C). 
In case of HA from human umbilical cord, incubated with rhHyal-2, clear differences in 
the degradation pattern compared to HA from S. zooepidemicus became obvious. The 
degradation did not stop at hyaluronan chain lengths of 20 kDa. Unfortunately, the end 
product of enzymatic digestion could not be identified, as the limit of detection was 
approximately 10 – 15 kDa (Fig. 3.5). 
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Fig. 3.5: Polyacrylamide gel electrophoresis and corresponding densitometric scan of HA from 
human umbilical cord (lane A) incubated with 20 µg lyophilized rhHyal-2 for 48 h (lane B) and 
0.0041 U/mL of rhHyal-1 for 24 h (lane C). 
These findings confirm the results from the viscosimetric measurements with respect to the 
suggestion, that there is a substrate dependency of enzymatic digestion by rhHyal-2.  
 
3.4. Summary and conclusions 
Recombinant human hyaluronidase-2 was expressed in DS-2 cells by analogy with the 
procedure reported by E. Hofinger (Hofinger, 2007). The protein was isolated from 
conditioned insect cell medium and purified by Ni-IMAC, which led to a product of 
sufficiently high purity. Since the reported method gave only rather low yields, a 
simplified and faster purification protocol was established. After dialysis and 
lyophilization of the elution fractions the presence of rhHyal-2 was proven by Western 
Blot analysis and the protein was characterized with respect to hyaluronan degrading 
activity. Moreover, a portion of the obtained purified protein was provided for monoclonal 
antibody production. 
As enzymatic activity was expected to be very low, a viscosimetric assay was set up. This 
method was favored for detection of Hyal-2 activity because of the significant decrease in 
viscosity, especially at the beginning of the hyaluronan degradation (Hoechstetter, 2005). 
Furthermore, viscosimetry was previously shown to be the most sensitive method among 
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the common hyaluronidase assays (Hofinger, 2007), and the colorimetric assay was 
reported by Lepperdinger et al. (1998) to apparently unveil inactivity of Hyal-2.  
The viscosimetric measurements clearly showed hyaluronan degrading activity of rhHyal-2 
at acidic conditions. The rather low activity is in agreement with previous publications, 
which suggested low, if any Hyal-2 activity in an acidic environment (Lepperdinger et al., 
1998; Vigdorovich et al., 2007). Strikingly, enzymatic activity of rhHyal-2 was dependent 
on the source of hyaluronan used. High molecular weight HA from S. zooepidemicus was 
digested slowly and to a lesser extent compared to HA from human umbilical cord, which 
is composed of shorter chain lengths. The latter was degraded pretty fast. This finding was 
confirmed by analytical investigations using polyacrylamide gel electrophoresis combined 
with alcian blue silver staining. With this method, the molecular weight of the generated 
HA fragments was estimated by comparing the migration of the fragments with those of 
sulphonated polystyrenes of known median sizes. Differences between both HA types were 
also detected using the electrophoresis method. By analogy with the results from 
viscosimetry, HA from human umbilical cord was degraded into smaller fragments by 
rhHyal-2 than HA from S. zooepidemicus. It may be speculated that these results reflect 
differences in the secondary and tertiary structure of both types of HA. Possibly the longer 
chains of the bacterial hyaluronan facilitates intramolecular interactions protecting against 
rhHyal-2 digestion to a certain extent. 
In summary, enzymatic activity of purified, lyophilized rhHyal-2, which is dependent on 
the source of hyaluronan used, was unequivocally demonstrated. Nevertheless, the 
physiological role of the rather weak activity is still totally unclear. 
It cannot be excluded that Hyal-2 has a preferential substrate other than HA, although 
Lepperdinger et al. found no enzymatic cleavage of structurally related carbohydrates such 
as chondroitin sulfates A, B and C, heparan sulfate or heparin (Lepperdinger et al., 1998). 
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Chapter 4 
Enzymatic activity of Hyal-2 in blood platelets 
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4.1. Introduction 
Platelets are anucleated cells derived from megakaryocytes and are the second most 
numerous corpuscles circulating in the blood. They are involved in several patho-
/physiological processes, namely haemostasis and thrombosis, inflammation, host defense 
and maintenance and regulation of the vascular tone (Harrison, 2005). Likely, the most 
important function of platelets is to seal openings in the vascular network. Upon vessel 
wall damage, platelets play a central role in a functional sequence, beginning with 
adhesion to collagen, which leads to activation and subsequent shape change from discoid 
to spiny spheres with filopodia. The change in shape goes along with secretion of protein 
(e.g. fibrinogen, plasminogen, PDGF, VEGF) and nonprotein mediators (ADP, Ca
2+
, 
serotonin), which are responsible for further platelet activation and stimulation of wound 
healing. In the past few years, the role of platelets in inflammatory conditions has been 
acknowledged, but this needs to be elucidated further. Platelets have been shown to 
contribute to inflammatory processes, for instance, in inflammatory bowel disease (IBD) 
(Danese et al., 2004), cardiovascular diseases (Lindemann et al., 2007) and 
neuroinflammatory disorders (Horstman et al., 2010). 
Previously, an association between platelet fractions and hyaluronidase activity was 
documented (Fiszer-Szafarz et al., 2000), but it remained unclear, which hyaluronidase 
isoform is responsible for the displayed activity. 
Recently, de la Motte et al. detected Hyal-2 as the only hyaluronidase expressed on platelet 
membranes and suggested that this isoenzyme is capable of cleaving hyaluronan into 
signalling fragments (de la Motte et al., 2009). The hyaluronan degrading activity was 
detected at neutral pH, which is in contrast to other published data on Hyal-2 activity 
(Lepperdinger et al., 1998; Vigdorovich et al., 2007; Vigdorovich et al., 2005). However, 
this result has been linked to inflammatory diseases, as HA fragment formation is observed 
under inflammatory conditions, such as arthritis (Poole and Dieppe, 1994) and in the 
intestinal mucosa of patients with IBD (de la Motte et al., 2003). Moreover, IBD is 
associated with reactive thrombocytosis (Shen et al., 2009) and increased leukocyte-
platelet interactions have been described (Irving and Rampton, 2007). 
Inspired by the results of de la Motte et al., in this work human platelet preparations were 
used as source of Hyal-2 to explore the enzymatic activity at different pH-values, the 
approximate size of generated fragments, differences in the degradation of HA from 
different sources and differences in enzymatic activity between non-activated and activated 
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platelets. The results from human platelets were compared to those obtained from 
investigations on murine platelets from Hyal-2 knockout and wildtype mice and to rhHyal-
2, respectively. 
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4.2. Materials and methods 
4.2.1. Isolation of human platelets 
Blood was collected from a forearm vein of a 28 year-old female, healthy volunteer into 
syringes containing citrate – citric acid – dextrose (CCD) (2.5 % trisodium citrate; 1.37 % 
citric acid monohydrate; 2.0 % glucose). The ratio of anticoagulant to blood was 2:8. After 
centrifugation at 200 g for 20 min at room temperature (RT), platelet-rich plasma (PRP) 
was carefully collected. Platelets were isolated from PRP by additional centrifugation at 
2000 g for 12 min at RT. The supernatant was discarded and the resulting platelet pellet 
was washed three times with the assay buffer (see 3.2.8). 
 
4.2.2. Isolation of murine platelets 
Murine blood was collected in ketamine/xylazine anesthesia by cardiac puncture into 200 
µL of Alsever´s buffer (0.8 % trisodium citrate; 0.05 % citric acid monohydrate; 2.0 % 
glucose; 0.42 % NaCl). Blood samples were centrifuged at 70 g for 15 min to collect the 
PRP. PRPs were centrifuged a second time to reduce contamination by red and white blood 
cells. After washing with hepes-buffer (20 mM hepes; 138 mM NaCl; 2.9 mM KCl; 1 mM 
MgCl2; 0.36 mM NaH2PO4), pH 7.4, platelets were used for investigations. 
 
4.2.3. Preparation of human platelet membranes 
Isolated platelets from 5 mL of PRP were resuspended in 5 mL of hypotonic buffer (5 mM 
EDTA; 5 mM tris in Millipore water, pH 7.4). The resulting suspension was dispersed in 
1.5 mL polypropylene tubes and frozen in liquid nitrogen. Platelets were allowed to thaw 
at room temperature, pooled and disrupted by ten manual strokes of a Potter Elvehjem 
model Potter S (B. Braun Melsungen AG, Melsungen, Germany). After repeating this step, 
the platelet homogenate was centrifuged for 30 min at 25000 rpm using a TGA-45 
ultracentrifuge, equipped with a TFT 45.94 rotor (Kontron Analytical, Zürich, 
Switzerland). The supernatant was removed and the pellet was re-suspended in 10 mL of 
hypotonic buffer and centrifuged again for 30 min at 25000 rpm. The resulting platelet 
membrane pellet was re-suspended in 5 mL of 1 mM KHCO3 solution. Protein content was 
determined using the Bio-Rad protein assay (Bio-Rad, Munich, Germany) based on the 
method of Bradford (Bradford, 1976). 100 µL aliquots of the membrane suspension were 
stored at -80 °C until use. 
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4.2.4. SDS-PAGE and Western Blot 
Electrophoresis and Western Blot analyses were performed as described in Chapter 3. 
 
4.2.5. 2-D gel electrophoresis 
Samples for 2-D electrophoresis were diluted with sample buffer (7 M urea, 2 M thiourea, 
2 % chaps, 0.5 % Bio-Lyse 3/10 ampholytes (100 x), 1 % Serdolit MB-1™ and 100 mM 
DTDE) and solubilized for 1 h at room temperature. After centrifugation at 13000 g for 30 
min at 15 °C, immobilized pH gel strips (IPG, ReadyStrip™ 7 cm, pH 3 – 10, Bio-Rad, 
Munich, Germany) were loaded with the sample and an IEF marker mix (pH 3.6 – 9.3, 
Sigma-Aldrich, Munich, Germany), respectively, and were re-hydrated for 11-16 h. 
Isoelectric focusing (IEF) was performed with a Bio-Rad Protean IEF cell (Bio-Rad, 
Munich, Germany) for 16.2 kWh at 20 °C. The IPG strips were soaked with equilibration 
buffer I for 15 min and subsequently transferred to equilibration buffer II (buffer 
compositions see Tab. 4.1) for another 15 min. The strips were loaded onto a 12% 
polyacrylamide gel (gel composition see Tab. 3.1) and SDS-PAGE was performed at 200 
V.  
Tab. 4.1: Composition of equilibration buffers for 2-D electrophoresis. 
 Urea (M) SDS (%) 
Tris/HCl 
pH 8.8 (M) 
Glycerol 
(%) 
DTT (%) 
Iodoacetamide 
(%) 
Buffer I 6 2 0.375 20 2 - 
Buffer II 6 2 0.375 20 - 2.5 
 
The gel was blotted on a nitrocellulose membrane or fixed in a solution containing 30 % 
(v/v) methanol, 10 % (v/v) acetic acid for silver staining. Western Blot analysis was 
performed as described above. For analysis of glycosylation the membrane was incubated 
with peroxidase conjugated lectin from Helix pomatia (Sigma-Aldrich, Munich, Germany). 
The chemiluminescence detection of peroxidase activity was carried out as described in 
3.2.7. Silver staining was performed as described in 3.2.9. 
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4.2.6. Gel permeation chromatography (GPC) 
Gel permeation chromatography was carried out using a Shimadzu (Shimadzu, Tokyo, 
Japan) LD-10 liquid chromatograph equipped with degasser, pump, auto-injector and 
column oven in combination with a TDA-300 triple detector (Viscotek, Malvern 
Instruments Ltd., Malvern, UK) operated in dual mode (refractive index, UV detection at 
210 nm). A BioSep-SEC-S 4000 column (Phenomenex Ltd., Aschaffenburg, Germany) 
was used as stationary phase and water and incubation buffer (see above) as mobile phase, 
respectively. The amount of HA in the injection volume of 10 µL was 25 ng. Column and 
detector were operated at 40 °C and the flow rate was 0.7 mL/min. To determine the size 
of HA fragments, dextrane standards with average molecular wheights of 5.2, 11.6, 20, 48 
and 148 kDa were used (Malvern Instruments Ltd., Malvern, UK). 
 
4.2.7. Viscosimetric and electrophoretic hyaluronidase activity assays 
Viscosimetry and polyacrylamide gel electrophoresis followed by combined alcian blue 
silver staining were performed as described in Chapter 3. 
 
4.2.8. Zymography 
Hyaluronan gel electrophoresis was performed as described by Cherr et al (Cherr et al., 
1996). SDS polyacrylamide gels were prepared as described in section 3.2.6 with 
additional 67 µg/mL hyaluronan (5 mg/mL stock solution) in the separation gel. Samples 
for zymography were mixed with sample buffer (200 mM tris/HCl pH 6.8, 20 % glycerol, 
10 % SDS, 0.05 % bromophenol blue) in a ratio of 1:1 and directly applied to the gel. After 
electrophoresis at 150 V for approximately 2 h, SDS was removed from the gel by shaking 
in 2.5 % triton X-100 for 30 min at RT, a short washing period in water and successive 
washing in incubation buffer for 30 min. After incubation in McIlvaine´s buffer, pH 4.0, 
the gel was stained with 0.5 % alcian blue in 7 % acetic acid for 1 h and destained in 7 % 
acetic acid until the regions of hyaluronan digest were visible. The gel was counterstained 
with Coomassie Brilliant Blue G-250 (Serva, Heidelberg, Germany). 
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4.2.9. Activation of platelets 
For platelet activation PRP was prepared as described above. After centrifugation, the 
resulting platelet pellet was re-suspended in hepes-buffer pH 7.4 (137 mM NaCl; 2.7 mM 
KCl; 10 mM hepes; 1.7 mM MgCl2; 25 mM glucose; 0.05 % BSA) containing 2 U/mL 
apyrase (Sigma-Aldrich, Munich, Germany) and 200 µM CaCl2. Platelets were incubated 
at 37 °C for 10 min before centrifuging at 1000 g for 15 min. After carefully re-suspending 
the pellet in buffer 1 mM CaCl2 (100 mM stock solution), 1 U/mL thrombin (Boehringer, 
Mannheim, Germany, 5 U/mL stock solution in Hepes-buffer) and 10 µg/mL collagen (MP 
Biomedicals, Heidelberg, Germany, 250 µg/mL stock solution) were added. The clot was 
washed with hepes-buffer and used for investigations. 
 
4.2.10. Ca2+ assay for measuring platelet activation 
For measuring platelet activation, the increase of intracellular Ca
2+
 after addition of 
mediators of platelet function was observed. Washed platelet suspensions in loading buffer 
(145 mM NaCl, 5 mM KCl, 10 mM Hepes, 1 mM MgSO4, 10 mM glucose, 0.1 % BSA, 
pH 7.4), containing 2 U/mL apyrase and 200 µM CaCl2, were loaded with fura-2/AM 
according to the following protocol. 1 µM fura-2/AM (Invitrogen, Karlsruhe, Germany, 1 
mM stock solution in anhydrous DMSO) and 5 µL of Pluronic
®
 F-127 (Calbiochem-
Novabiochem Corporation, La Joila, Canada, 20 % stock solution in DMSO) were added 
to 1 mL of cell suspension. After 45 min of incubation in the dark at room temperature, 12 
µL of ACD were added to the suspension. The cells were centrifuged at 700 g for 20 min 
at room temperature and re-suspended in the same volume of loading buffer containing 2 
U/mL apyrase. The resulting suspension was incubated for another 30 min in the dark to 
ensure complete intracellular cleavage of the acetoxymethyl (AM) ester groups. Platelets 
were washed and re-suspended in loading buffer. 1 mL of the platelet suspension was 
diluted in a cuvette with 0.98 mL loading buffer and 20 µL of 100 mM CaCl2. 
Measurements were performed in a LS 50 B spectrofluorimeter (PerkinElmer, Überlingen, 
Germany) under continuous stirring at 25 °C at low speed. Instrumental settings were: λex: 
340 and 380 nm alternating with slit 10 nm and λem: 510 nm with slit 10 nm. The baseline 
was recorded for approximately 20 s before challenging the loaded cells by thrombin 
(Böhringer, Mannheim, Germany), collagen (MP Biomedicals, Solon, USA) and the 
thrombin receptor activator peptide SFLLRN (Bachem AG, Bubendorf, Switzerland), 
respectively. The PAR1 antagonist peptide YFLLRNP (Bachem AG, Bubendorf, 
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Switzerland) was incubated with the cells for 15 min in the dark at room temperature prior 
to measurement. For the calculation of intracellular Ca
2+
 the Grynkiewcz equation was 
used (Grynkiewicz et al., 1985): 
          
        
        
     
Eq. 4.1 
with KD being the dissociation constant of fura-2-Ca
2+
 (225 nM), R the ratio of 
fluorescence intensity at 510 nm after excitation at 340 and 380 nm, Rmax the fluorescence 
ratio at saturating Ca
2+
 concentration, determined after adding 10 µL of digitonin (2 % in 
water, Sigma-Aldrich, Munich, Germany), which causes lysis of the cells and saturation of 
the dye with the Ca
2+
-ions present in the mixture in the cuvette, Rmin the fluorescence ratio 
of Ca
2+
-free dye, determined after addition of 50 µL of EGTA (600 mM in 1M Tris/HCl 
buffer, pH 8.7) to the lysed cells and SFB a correction factor, which accounts for the ratio 
of fluorescence intensity at 510 nm after excitation at 380 nm of the Ca
2+
-free and Ca
2+
- 
saturated dye. 
 
4.3. Results and discussion 
4.3.1. SDS-Page and Western Blot analysis of Hyal-2 in human platelets 
In order to verify the findings of de la Motte et al. (de la Motte et al., 2009), who stated 
that Hyal-2 is the only hyaluronidase in platelets, Western Blot analysis was performed. 
Using a primary anti-Hyal-2 antibody, two immunoreactive bands with apparent molecular 
weights of 54 and 44 kDa, respectively, were detected (Fig. 4.1, left). Purified recombinant 
human Hyal-1 expressed in DS-2 cells (Hofinger et al., 2007) (rhHyal-1) was utilized as a 
control to exclude crossreactivity of the antibody. rhHyal-1 was detected with anti Hyal-1 
serum, kindly provided by Prof. Dr. Robert Stern, UCSF (Fig. 4.1, right). 
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Fig. 4.1: Western blot analysis of Hyal-2 (left) and Hyal-1(right) in human platelets (lane A). 
rhHyal-1 (lane B) was used as negative (for anti-Hyal-2) and positive (for anti-Hyal-1) control, 
respectively 
In accordance with the literature, Hyal-2 was detected as the only hyaluronidase in human 
platelets with no evidence for Hyal-1. The antibody against Hyal-2 did not show cross-
reactivity with Hyal-1 and vice versa. 
 
4.3.2. 2-D gel electrophoresis 
For the determination of the properties of Hyal-2 in human platelet membrane 
preparations, 2-D electrophoresis was performed. In the following Western blot analysis 
two spots with a molecular weight of 54 kDa, corresponding to the calculated mass of 
Hyal-2, were detected. The pI of the two isoforms was 7.9 and 8.2, respectively. Lectin 
blotting showed that both isoforms exist as glycosylated proteins (Fig. 4.2). 
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Fig. 4.2: 2-D electrophoresis of human platelet membrane preparations. A) Silver staining, B) 
Western blot analysis. Anti-Hyal-2 polyclonal antibody was used as primary antibody, HRP-
conjugated anti-rabbit-IgG as secondary antibody and detection was achieved by ECL, C) Lectin 
blot analysis. HRP-conjugated lectin from Helix pomatia was used as antibody and detection was 
achieved by ECL. 
In contrast to the one-dimensional Western Blot analysis, there was no protein with a 
molecular weight of 44 kDa detected in the 2-D analysis. This result supports the 
suggestion that during one-dimensional SDS-PAGE sample preparation protein 
degradation takes place, as there is no heating of the samples during 2-D electrophoresis. 
 
4.3.3. Detection of enzymatic activity of Hyal-2 in non-activated human platelets by 
viscosimetry 
The determination of the decrease in viscosity during degradation of hyaluronan is the 
most sensitive method to investigate hyaluronidase activity (Hofinger, 2007). Therefore, a 
viscosimetric assay was established to find HA degrading activity in human platelets.  
The optimal pH for Hyal-2 activity is discussed very controversially in literature. 
Therefore, firstly, mixtures containing HA from S. zooepidemicus and washed human 
platelets were incubated for 48 h under acidic (pH 4.0, and pH 5.0) and neutral (pH 7.0) 
conditions to determine the appropriate pH value for further investigations. At pH 4.0 the 
incubation mixtures containing human platelets showed a stronger decrease in viscosity 
compared to the negative control without platelets. At pH 5.0 and pH 7.0 there was no 
difference between the negative control and platelet containing incubation mixtures, thus 
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no HA degrading activity was detectable (Fig. 4.3). Therefore, all following experiments 
were performed under acidic conditions. 
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The hyaluronan degrading activity of isolated and washed human platelets was compared 
to that of rhHyal-1 (0.42 mU/mL). The low activity of rhHyal-1 was chosen, because 
contamination by traces of plasma Hyal-1 in the platelet preparations could not be 
excluded at that time. Hyaluronidase levels in human serum from healthy volunteers range 
from 3 mU/mL (Natowicz and Wang, 1996) to 9 mU/mL (Laudat et al., 2000). Platelet 
associated hyaluronidase activity became obvious within 24 h, but at a much slower rate 
than that of rhHyal-1 (Fig. 4.4, A). Enzymatic activity was also compared to that of a 
human platelet preparation, which was inactivated by heating at 100 °C for 15 min, as 
viscosity always decreased to a minimal extent, even without enzyme. The decrease in 
viscosity generated by human platelets differed significantly from that observed for 
inactivated platelets (p = 0.007). 
Fig. 4.3: Viscosimetry of HA digestion mixtures with 
human platelets incubated at 37 °C for 24 h at different 
pH values (grey bars). The HA was of microbial origin 
(S. zooepidemicus). The black bars represent reference 
HA mixtures incubated at 37 °C for 24 h. A) pH 4.0, B) 
pH 5.0, C) pH 7.0 
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Fig. 4.4: Viscosimetric analyses of hyaluronidase activity. A: human platelets (squares) compared 
to 0.42 mU/mL rhHyal-1(triangles) and heat-inactivated platelets (circles), respectively. B: Human 
platelet membrane preparation (squares) compared to heat-inactivated membranes (circles). Error 
bars represent SEM of 3 independent experiments. The used hyaluronan was from S 
zooepidemicus. 
Hyal-2 has been suggested to be a GPI-anchored protein on the cell-membrane (Rai et al., 
2001). Consequently, viscosimetric analysis of Hyal-2 activity was also performed with 
human platelet membrane preparations. In comparison to the substrate mixture incubated 
with inactivated membranes, viscosity decreased significantly (p = 0.003) within 24 h (Fig. 
4.4, B) 
These results prove that Hyal-2 is catalytically active in human platelets and that it is 
present in platelet membrane preparations. The enzyme displays highest activity at pH 4. 
Therefore, Hyal-2 should be located in an acidic microenvironment to be active under 
physiological conditions. As Hyal-2 is associated with specialized microdomains in the 
plasma membrane, so-called lipid rafts (Andre et al., 2011), the interaction of CD44 with 
the Na
+
-H
+
-exchanger NHE1 in the presence of HA could play an important role. 
Bourgignon et al. detected complexed CD44 and NHE1 in lipid rafts after treatment of 
MDA-MB-231 cells with hyaluronan, but no association without HA-treatment. The 
authors suggested that HA recruits signaling complexes, including NHE1 and RhoA-
A B 
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activated Rho kinase (ROK) into lipid rafts of the cells used (Bourguignon et al., 2004). 
This could also happen in platelets, which express rather high amounts of NHE1 
(Rutherford et al., 1997). For platelet-associated Hyal-2 activity the hyaluronan receptor 
CD44 also could play an important role. CD44 is able to mediate the adhesion of platelets 
to HA (Koshiishi et al., 1994). Therefore the HA receptor could bring membrane bound 
Hyal-2 close to its substrate in the extracellular matrix. We also confirmed the expression 
of CD44 in human platelet membrane preparations with a molecular weight of 
approximately 85 kDa, which correlates well with the calculated mass of isoform 1 (81.5 
kDa) (Fig. 4.5). The second immunoreactive band is of a molecular mass of about 170 
kDa, which is approximately double the mass of a CD44 monomer. HA is an extremely 
multivalent ligand and therefore clustering of monomeric receptors into a multimeric 
complex could increase the avidity to such a ligand (Perschl et al., 1995; Sleeman et al., 
1996). 
 
 
Fig. 4.5: Presence of CD-44 in human platelet membranes determined 
by Western blotting. Anti-CD44 monoclonal antibody was used as 
primary antibody, HRP-conjugated anti-rabbit IgG as secondary 
antibody and detection was achieved by ECL 
 
 
4.3.4. Dependency of substrate degradation by platelet-derived Hyal-2 on the source 
of HA 
By analogy with the investigation of the recombinant enzyme, the activity of platelet-
associated Hyal-2 was determined with hyaluronan from different sources. We used the 
kinetic viscosimetric assay to reveal differences in the degradation of HA from S. 
zooepidemicus, HA from human umbilical cord and from rooster comb, respectively. 
Actually, the results were in agreement with those for the recombinant enzyme (Fig. 4.6). 
Hyaluronan from microbial origin was degraded slower and to an apparently lesser extent 
than HA from vertebrate sources (Tab. 4.2). 
 
 
 
 Results and discussion 
 - 48 - 
Tab. 4.2: Decrease in ηrel (%) per h using different sources of hyaluronan. Platelet derived Hyal-2 
compared to rhHyal-2. 
source of HA S. zooepidemicus human umbilical cord rooster comb 
human platelets 2.0 3.1 2.7 
rhHyal-2 1.7 3.1 n. d. 
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Fig. 4.6: Viscosimetric analyses of enzymatic 
activity of platelet-derived Hyal-2 using 
hyaluronan from different sources: HA of 
microbial origin (circles), HA from human 
umbilical cord (squares) and HA from rooster 
comb (triangles). 
 
 
4.3.5. Gel permeation chromatography for determination of hyaluronan fragments 
generated by platelet-associated Hyal-2 
To determine the size distribution of the generated hyaluronan fragments, gel permeation 
chromatography was performed. The incubation mixtures of hyaluronan with human 
platelets, rhHyal-1 and bovine testicular hyaluronidase (BTH, Neopermease
®
) were 
separated with a BioSep-SEC-S 4000 column. As there were hardly any differences 
between the chromatograms (Fig. 4.7), this approach was discontinued. 
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Fig. 4.7: Gel permeation chromatography of hyaluronan incubation mixtures with human platelets, 
rhHyal-1 and BTH, respectively 
 
4.3.6. Determination of enzymatic activity of Hyal-2 in non-activated human 
platelets by electrophoresis 
In order to verify the results from the viscosimetric analyses by an additional method and 
to get a hint regarding the HA fragment size resulting from degradation by Hyal-2, 
electrophoretic investigations were performed. Platelet mediated hyaluronan degradation 
was compared to the action of rhHyal-1 and BTH, respectively, and the approximate size 
of the generated fragments was determined by comparing the migration of the fragments 
with those of sulphated polystyrenes of known sizes. Fig. 4.8 shows a typical gel and the 
corresponding densitometric scans. As expected, rhHyal-1 and BTH degrade HA into 
fragments smaller than 17 kDa, whereas fragments generated by human platelets appear to 
have a minimal size of 17 kDa after incubation for 48 h. This finding correlates with the 
results of Lepperdinger et al., who found a size limit of 20 kDa or 50 disaccharides 
(Lepperdinger et al., 2001; Lepperdinger et al., 1998). Surprisingly, when incubations were 
performed with isolated platelet membrane fractions, HA degradation appears to result in 
fragments of a smaller size (Fig. 4.9). 
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Fig. 4.8: PAGE and corresponding densitometric scans of hyaluronan (lane A) incubated with 
human platelets at 37 °C for 48 h (lane B), 0.0042 U/mL rhHyal-1 at 37 °C for 2 h (lane C) and 10 
IE/mL BTH at 37 °C for 2 h (lane D) 
 
Fig. 4.9: PAGE and corresponding densitometric scans of hyaluronan (lane A) incubated with 
human platelet membranes at 37 °C for 48 h (lane B) 
 
4.3.7. Zymography 
The Western Blot analysis of human platelets revealed two immunoreactive bands of 
different molecular mass. The two proteins were investigated for hyaluronidase activity 
using SDS substrate-PAGE with hyaluronan immobilized in the separating gel. 
 Enzymatic activity of Hyal-2 in blood platelets 
 - 51 - 
Zymography revealed that only the 54 kDa protein exhibited hyaluronan degrading 
activity. Enzymatic activity was compared to that of 2.5 mU/mL rhHyal-1 which also 
displays one active protein band with a molecular mass of 55 kDa (Fig. 4.10). 
 
 
Fig. 4.10: Substrate gel analysis of 0.5 mg/mL human 
platelets (lane B) compared to 2.5 mU/mL rhHyal-1 
(lane A), counterstained with coomassie 
 
This result supports the suggestion that during SDS-PAGE sample preparation degradation 
of the protein takes place. The resulting protein fragment is not able to display enzymatic 
activity anymore. 
 
4.3.8. Activation of human platelets 
As platelets change their shape, form aggregates and secret their granule contents during 
activation, the question arose, if Hyal-2 activity changes along with platelet activation. For 
this reason platelets were stimulated with different platelet activation mediators and 
intracellular Ca
2+
-levels were measured to control activation. Platelet activation was 
achieved by adding 1 U/mL thrombin, 50 µM ADP and 33.5 µM of the thrombin receptor 
activator peptide 6 (SFLLRN), respectively.  
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Fig. 4.11: Ca
2+
-mobilization in human platelets by adding: A: 1 U/mL thrombin, B: 50 µM ADP  
and C: 33.5 µM SFLLRN, respectively. D: Blocking of thrombin mediated PAR1 activation was 
achieved by 15 min preincubation with 5 µM YFLLRNP 
Thrombin signalling in platelets has been proposed to be mediated by proteinase activated 
receptors 1 and 4 (PAR1, 4). Therefore, a PAR1-agonistic peptide (SFLLRN) was used to 
control Ca
2+
-mobilization mediated by PAR1. Preincubation of the platelets with a PAR1 
blocking peptide (YFLLRNP) showed that addition of thrombin did not trigger Ca
2+
-
mobilization anymore (Fig. 4.11). Thus, in human platelets the thrombin triggered increase 
in intracellular Ca
2+
 was the result of PAR1 activation. 
 
4.3.9. Hyaluronan degradation by Hyal-2 in activated human platelets 
Viscosimetric measurements could not be performed with activated platelets because the 
resulting platelet clot would lead to a plug in the capillary of the used viscosimeter. Thus, 
only electrophoretic investigations were carried out. Incubation mixtures containing 
hyaluronan from S. zooepidemicus and activated or non-activated human platelets were 
used and compared to the migration pattern of HA fragments generated by rhHyal-1. In 
Fig. 4.12 the migration pattern of the samples are shown.  
C D 
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Fig. 4.12: PAGE and corresponding densitometric scan of hyaluronan from S. zooepidemicus (lane 
A) incubated with activated human platelets (lane B), non-activated human platelets (lane C). 
Incubation conditions were: 37 °C, 72 h. Migration patterns were compared to HA fragments 
generated by 0.0042 U/mL rhHyal-1 (lane D). Incubation conditions: 37 °C, 24 h 
Apparently, there is a difference in the migration patterns of HA fragments generated by 
activated or non-activated platelets. It seems that activated human platelets are also able to 
degrade hyaluronan, but to a lesser extent than non-activated platelets. Although the 
protein content could not be reliably determined, because collagen was used for platelet 
activation, platelet numbers in the incubation mixtures were the same. 
Another explanation for the different activities could be that Hyal-2 might be concentrated 
in platelet microparticles
1
 (PMPs), which are produced and released during platelet 
activation (Warren and Vales, 1972; Wolf, 1967), especially after activation with strong 
agonists like thrombin and collagen (Nomura, 2001), which were used in this study.  
 
4.3.10. Detection of enzymatic activity of Hyal-2 in murine platelets by viscosimetry 
As contamination of platelet preparations with plasma Hyal-1 cannot be excluded, platelet 
preparations from Hyal-2 knock-out (KO) mice (Jadin et al., 2008) were used to assess the 
effectiveness of Hyal-1 removal by extensive washing. Hyal-2 KO mice displayed 
moderate thrombocytopenia (443  106 vs. 1175  126 x 103/µL). This was taken into 
account in further investigations by diluting platelet preparations from wildtype (WT) mice 
accordingly. Dilution was controlled by determination of the protein content in the samples 
with the BCA assay. Fig. 4.13 shows that viscosimetric measurements with wildtype 
                                                 
1
 Prof. Dr. B. Flamion, Namur (Belgium), personal communication 
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platelets resulted in a significantly lower viscosity (P = 0.026) after an incubation time of 
72 h in comparison to incubation mixtures containing Hyal-2 KO platelets. Plasma from 
Hyal-2 KO mice was investigated to confirm functional Hyal-1 expression in these 
animals. 
incubation time (h)
0 20 40 60

re
l 
(%
)
0
20
40
60
80
100
*
 
 
Fig. 4.13: Viscosimetric analysis of enzymatic 
activity in murine wildtype platelets (squares) 
compared to Hyal-2 KO platelets (triangles) and 
plasma Hyal-1 from Hyal-2 KO mice (circles). 
Error bars represent SEM of 3 independent 
experiments. 
 
4.3.11. Detection of hyaluronan fragments generated by murine platelet-derived Hyal-
2 using electrophoresis 
Polyacrylamide gel electrophoresis with subsequent combined alcian blue silver staining 
was performed to visualize differences in hyaluronan fragmentation by wildtype and Hyal-
2 KO platelets, respectively. Plasma Hyal-1 from Hyal-2 KO mice served as positive 
control. As negative control an incubation mixture without platelets or plasma, incubated 
as long as the fragmentation samples, was used. Fig. 4.14 clearly shows the differences in 
the fragmentation pattern between the respective samples. There was no difference in the 
migration pattern between HA incubated alone and HA treated with platelets from Hyal-2 
KO mice. Wildtype platelets are able to degrade hyaluronan to an approximate size of 17 
kDa, which is also consistent with the findings of Lepperdinger et al. (Lepperdinger et al., 
2001; Lepperdinger et al., 1998). Hyal-2 KO mice functionally express Hyal-1, which is 
present in plasma and degrades HA into small oligosaccharides. 
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Fig. 4.14: PAGE and corresponding densitometric scans of hyaluronan from umbilical cord (lane 
A) incubated with Hyal-2 KO platelets (lane B), platelets from wildtype mice (lane C) and plasma 
from Hyal-2 KO mice (lane D), respectively. Incubation conditions were: 37 °C, 72 h. 
 
4.3.12. Hyaluronan degradation by Hyal-2 derived from activated murine platelets 
By analogy with activated human platelets only an electrophoretic assay was performed in 
case of activated murine platelets. There was a slight difference in the migration pattern of 
non-activated and activated wildtype platelets. Non-activated platelets apparently degrade 
HA to smaller fragments than activated ones (Fig. 4.15). This observation is consistent 
with the results obtained from activated human platelets and supports the speculation about 
Hyal-2 being released in PMPs during activation. But this suggestion has to be investigated 
in more detail by isolating PMPs after platelet activation and detecting Hyal-2 in the 
microparticles.  
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Fig. 4.15: PAGE and corresponding densitometric scans of hyaluronan from umbilical cord (lane 
A) incubated with non-activated wildtype platelets (lane B), activated wildtype platelets (lane D), 
non-activated Hyal-2 KO platelets (lane C) and activated KO platelets (lane E). Incubation 
conditions were: 37 °C, 72 h. 
 
4.4. Summary and conclusion 
As de la Motte et al. reported that Hyal-2 is the only hyaluronidase expressed in platelets 
with no evidence for Hyal-1 (de la Motte et al., 2009), platelets were chosen as source for 
Hyal-2. Due to the controversial discussion with respect to Hyal-2 activity (Bourguignon et 
al., 2004; de la Motte et al., 2009; Harada and Takahashi, 2007; Lepperdinger et al., 1998; 
Vigdorovich et al., 2007; Vigdorovich et al., 2005) we investigated non-activated human 
and murine platelets particularly with regard to HA degrading activity. Hyaluronidase-2 
expressed in human platelets appears to consist of two glycosylated isoforms with different 
pI values.  
The significant decrease in HA viscosity, particularly at the beginning of the degradation 
reaction (Hoechstetter, 2005) as well as the high sensitivity of the assay favors the use of 
viscosimetry for the detection of Hyal-2 activity. Human platelet-rich plasma preparations 
were extensively washed to isolate platelets and remove residual plasma Hyal-1. 
Incubations of HA with washed non-activated platelets showed a significantly higher 
decrease in viscosity compared to HA incubations with heat-inactivated platelets at acidic 
pH. The results obtained from investigations with human platelets were consistent with 
those obtained from investigations with rhHyal-2. Enzymatic activity depended on the 
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source of hyaluronan used; HA from microbial origin was degraded slower and to a lesser 
extent than HA from vertebrate origin.  
To get reliable data, additionally murine platelet preparations were investigated. 
Particularly interesting was the comparison between HA degrading activity of wildtype 
platelets and Hyal-2 knock out platelets. We can exclude false positive results by the action 
of residual plasma Hyal-1 as only the HA incubations containing wildtype platelets, 
corrected for platelet counts, showed a decrease in viscosity within 72 h.  
Furthermore, activated platelet preparations were used to determine if there is a difference 
in hyaluronan degrading activity between activated and non-activated platelets. The 
obtained results led us to the suggestion, that Hyal-2 might be released in platelet 
microparticles during activation, because the generated fragments from HA incubation 
with activated platelets seemed to be greater in the performed electrophoretic assay, 
compared to those from incubations with non-activated platelets. This could be observed 
with both types of platelets, human and murine. Hyal-2 is associated with lipid rafts in the 
plasma membrane (Andre et al., 2011) and PMPs are produced after platelet activation by 
e.g. thrombin and collagen, they contain several components of the platelet membrane 
(Nomura, 2001), so Hyal-2 could be concentrated in the microparticles. This speculation 
needs to be verified in further investigations using isolated PMPs. 
Previously, platelet membranes were demonstrated to be able to induce airway smooth 
muscle cell (ASMC) proliferation (Svensson Holm et al., 2011) and very recently, the 
influence of HA on platelet-induced ASMC proliferation was investigated. The presence of 
platelets causes a significant increase in the proliferation of ASMC after 24 h of 
coincubation and this could be reduced by adding a CD44 blocking antibody. Additionally, 
ASMC were found to synthesize considerable amounts of HA and it was concluded that 
the interaction between ASMC derived HA, platelets and CD44 causes enhanced 
proliferation (Svensson Holm et al., 2012). Thus, we propose, that platelet-derived Hyal-2 
degrades hyaluronan synthesized by ASMC to fragments that can stimulate proliferation, 
which can be mediated by a signaling pathway through CD44 like described by Slevin et 
al. (Slevin et al., 2007). A hypothetical model is shown in Fig. 4.16. Such interactions 
could also take place with other proliferating cells. 
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Fig. 4.16: Possible interaction of platelets with ASMC and CD44 cell signalling pathway modified 
from Slevin et al. (Slevin et al., 2007). Hyaluronan synthase produces hyaluronan, which is bound 
by CD44 on the platelet membrane. NHE1 supplies acidic microenvironment (Bourguignon et al., 
2004) necessary for platelet-derived Hyal-2 activity. Hyaluronan fragments generated by Hyal-2 
bind to CD44 on ASMC membrane and trigger complex cell signalling pathway that leads to cell 
proliferation. 
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Chapter 5 
Determination of Hyal-2 activity in red blood 
cells 
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5.1. Introduction 
Red blood cells, also called erythrocytes, are derived from hematopoietic stem cells in the 
bone marrow and are anucleated biconcave disc shaped cells in their mature form. The 
cells are highly specialized and well adapted for their primary function of transporting 
oxygen from the lungs to all of the body tissues. The red blood cell is enclosed in a thin 
membrane that is composed of chemically complex lipids, proteins, and carbohydrates in a 
highly organized structure. 
Erythrocytes express several adhesion molecules on their surface, like ICAM-4, CD44 and 
CD47 (Spring and Parsons, 2000), but they are generally considered to be nonadhesive to 
endothelial surfaces. However, in several pathologic conditions, adhesion of erythrocytes 
to the vascular endothelium is increased. For example, red blood cells in sickle cell disease 
and erythrocytes infected with Plasmodium falciparum have an increased binding to host 
endothelial cells and sequester in postcapillary venules, likely contributing to the fetal 
complication of cerebral malaria (Hebbel, 1991; Pasloske and Howard, 1994). As a 
hyaluronan receptor CD44 could contribute to red blood cell binding to the ECM.  
Red blood cells were also found to tether to and roll on HA under shear conditions and this 
interaction was demonstrated to be mediated by CD44 (Kerfoot et al., 2008).  
To our knowledge, there are no studies dealing with hyaluronidase activity in red blood 
cells, so far. Thus, we investigated human and murine red blood cells and their ghost 
membranes with respect to Hyal-1 and Hyal-2 expression and performed enzymatic 
activity assays in analogy to platelets described in Chapter 4. 
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5.2. Materials and methods 
5.2.1. Isolation of human and murine red blood cells 
Blood was collected and centrifuged as described in Chapter 4. After careful removal of 
the buffy coat, the red blood cell (RBC) fraction was washed five times with 0.9 % NaCl 
solution by centrifuging at 1000 g for 15 min. 
 
5.2.2. Determination of RBC number in murine blood 
The number of RBC in murine blood was determined using a Neubauer counting chamber. 
Therefore washed RBC were diluted 200-fold with Hayem´s solution (0.25 % HgCl2, 2.5 
% Na2SO4, 0.5 % NaCl) using a RBC pipette. After careful mixing, and discarding a few 
drops, a small volume of the RBC dilution was introduced under the coverslip, which was 
placed on the counting chamber. Cells were allowed to settle for 5 min before counting. 
 
5.2.3. Preparation of erythrocyte ghost membranes 
500 µL of washed, packed RBC´s were suspended in 10 mL of ice-cold 5 mM phosphate 
buffer (pH 8.0) and centrifuged at 9000 g for 20 min at 4 °C. The hemolytic fraction was 
discarded and the operation was repeated at least 5 times until the supernatant appeared 
colorless. Centrifugation was then increased to 20000 g and washing was repeated until the 
ghost membranes appeared yellow-whitish. Membranes were re-suspended in 1 mL of 
buffer stored at -80 °C until use. 
 
5.2.4. SDS-PAGE and Western Blot analysis 
Electrophoresis and immunodetection of Hyal-2 in RBC membranes was performed as 
described in Chapter 3. Primary antibodies for Western Blot analysis were: rabbit 
polyclonal anti-Hyal-2 (Abcam, Cambridge, UK) and mouse monoclonal anti-Hyal-1 
(1D10) (Santa Cruz Biotechnology Inc., Santa Cruz, USA). Secondary antibodies were 
donkey anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc.) and goat anti-mouse IgG-
HRP (Fc specific) (Sigma-Aldrich, Munich, Germany), respectively. 
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5.2.5. Viscosimetry and PAGE for determination of Hyal-2 activity in RBC 
Hyaluronidase assays were the same as in Chapter 3. 100 µL of washed, packed RBC, 1 
mL of RBC membrane preparation and 50 µL of plasma were used for incubations, 
respectively. 
 
5.3. Results and discussion 
5.3.1. Identification of Hyal-2 in RBCs and RBC membranes by immunodetection 
By analogy with platelets, RBC´s and RBC membranes were investigated with respect to 
Hyal-2 expression by immunodetection using an anti-Hyal-2 and an anti-Hyal-1 primary 
antibody, respectively. 
 
Fig. 5.1: Immunodetection of Hyal-1 (left) and Hyal-2 (right) in murine RBC (lane B), murine 
RBC membranes (lane C) and human RBC (lane D). rhHyal-1 (lane A) and rhHyal-2 (lane E) 
served as positive controls. Primary antibodies were polyclonal anti-Hyal-2 and monoclonal anti-
Hyal-1. Secondary antibodies were HRP-conjugated and detection was achieved by ECL. 
As in platelets, Hyal-2 is the only hyaluronidase expressed in human and murine RBC, 
respectively. Western Blot analysis showed two immunoreactive bands with a molecular 
mass of approximately 60 and 45 kDa (Fig. 5.1). 
There was evidence for Hyal-1 expression neither in RBC membranes, nor in whole, 
washed RBC´s. Hence, RBC´s were investigated with respect to hyaluronidase activity. 
 
5.3.2. Hyaluronidase activity assays of Hyal-2 in RBC 
At first, a viscosimetric assay using whole washed murine RBC´s as sample was 
performed. Surprisingly, relative viscosity decreased dramatically after an incubation time 
of 20 h. The decrease in viscosity in the presence of 100 µL of RBC´s was even stronger in 
comparison to incubation mixtures containing 50 µL of murine plasma. PAGE with 
combined alcian blue silver staining revealed that fragments generated by RBC´s were 
smaller than 15 kDa, the determination of the fragment size was not possible (Fig. 5.2). 
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Although washed RBC preparations were able to degrade hyaluronan, we suppose that the 
observed enzymatic activity was due to contamination with Hyal-1 from residual plasma in 
the preparation. RBC´s are used to visualize HA-rich pericellular coats; this would not be 
possible, if RBS´s displayed such a high hyaluronidase activity (Clarris and Fraser, 1968; 
Knudson and Toole, 1985). Erythrocytes are very sensitive and should not be centrifuged 
at high speed to avoid severe damage. This explains why, despite careful separation, traces 
of plasma including Hyal-1 could not be completely removed. 
 
Fig. 5.2: Viscosimetric and electrophoretic analyses of incubation mixtures containing HA from S. 
zooepidemicus. A: control without sample at t = 20 h, B: 100 µL of murine RBCs at t = 20 h, C: 50 
µL of murine plasma at t = 20 h. 
 
5.3.3. Hyaluronidase activity assay of Hyal-2 in RBC membranes 
Because of the surprising results of the viscosimetric investigations using whole 
erythrocytes, RBC membranes, which also contain Hyal-2, were investigated with respect 
to enzymatic activity. RBC membranes from wildtype and Hyal-2 KO mice were used for 
comparison. Prior to membrane preparation, RBC count was determined and equal 
amounts were used. Incubations were performed at different pH values considering 
potential differences in the pH dependency of Hyal-2 in RBC membranes and Hyal-2 in 
platelet membranes. As becomes obvious from Fig. 5.3 there were no marked differences 
in the degradation pattern. HA and murine RBC membranes were incubated for 72 h at 
different pH values. Comparable results were obtained, when using human RBC 
membranes (data not shown). 
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The results from the electrophoretic analysis obtained with RBC membranes support the 
suggestion that the activities obtained with whole RBC´s were due to residual plasma 
Hyal-1 in the sample.  
 
5.4. Summary and conclusion 
By analogy with platelets, red blood cells only express Hyal-2 with no evidence for Hyal-1 
as determined by immunodetection. Thus, enzymatic Hyal-2 activity was investigated with 
RBC´s and RBC membranes, respectively, using viscosimetric and electrophoretic 
methods.  
Viscosimetric measurements with whole RBS´s showed a surprisingly high HA degrading 
activity, which was considered as residual plasma Hyal-1 activity due to insufficient 
washing of the highly sensitive erythrocytes. Therefore, RBC ghost membranes were 
prepared and incubated with HA at different pH-values, to exclude, that possible Hyal-2 
activity in RBC membranes is different compared to platelet preparations.  
The performed electrophoretic assay revealed no hyaluronan degrading activity derived 
from RBC membranes at any pH tested, indicating that the results obtained with whole 
RBC´s were really due to Hyal-1.  
These results support speculations that either RBC associated Hyal-2 is not involved in 
hyaluronan degradation, but has other functions in the erythrocytes. Alternatively, there 
exists a not yet characterized inhibitor, which may be inactivated to switch onHyal-2 
activity under certain physiological conditions  
Fig. 5.3: PAGE with combined alcian 
blue silver staining for determination of 
Hyal-2 activity in murine RBC 
membranes. Investigations were 
performed with HA from rooster comb 
(lane A) incubated with membranes 
from wildtype (lanes B – E) and Hyal-2 
KO RBC´s (lanes F – I) at pH 4.0 
(lanes B, F), pH 5.0 (lanes C, G), pH 
6.0 (lanes D, H) and pH 7.0 (lanes E, I), 
respectively. Incubation conditions 
were: 37 °C, 72 h. 
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Investigations on the effect of hyaluronan 
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6.1. Introduction 
Many physiological and pathophysiological processes including wound healing, tissue 
repair, tumor growth and vascular diseases are associated with angiogenesis (Folkman, 
1995). Moreover, hyaluronan and HA oligosaccharides have been demonstrated to play a 
role in the proliferation of several different cell types and in angiogenesis. Mostly, HA 
induced cell proliferation was correlated with the expression of CD44 on the cell surface.  
The involvement of HA in angiogenesis was first suggested by West et al., who observed 
that degraded HA products with a length of 4 – 25 disaccharide units stimulated wound 
healing in vivo (West et al., 1985). Later, it was reported that semi-purified HA fragments 
consisting of 3 – 16 disaccharide units were able to stimulate proliferation and migration of 
endothelial cells, while non-degraded HA showed the opposite effect (West and Kumar, 
1989). Trochon et al. studied the effect of a monoclonal CD44 antibody on two different 
endothelial cell lines and concluded that the cell surface receptor CD44 is involved in 
endothelial cell proliferation (Trochon et al., 1996). 
Furthermore, hyaluronan was shown to induce proliferation of human melanoma cells, 
thereby CD44 was the principle mediator of this effect (Ahrens et al., 2001).The 
interaction of HA and CD44 enhanced the proliferation of biliary epithelial cells (BEC), 
which was determined by treating immortalized mouse intrahepatic BEC with HA and 
antagonizing the effects with an anti-CD44 antibody (He et al., 2008). The proliferation of 
undifferentiated progenitor cells was also enhanced through HA mediated CD44 signalling 
(Hamann et al., 1995). David-Raoudi et al. demonstrated increased proliferation of human 
dermal fibroblasts by addition of HA fragments containing 6 and 440 disaccharide units. 
The strongest effect occurred at a concentration of 10 – 50 µg/mL. The authors suggested 
an implication of CD44, although the involvement of other receptors was not ruled out 
(David-Raoudi et al., 2008). 
The aim of this study was to investigate possible effects of HA fragments generated by 
human platelet-derived Hyal-2 on the proliferation of human endothelial cells. 
Additionally, the effect of HA digests prepared with BTH and rhHyal-1 were investigated, 
and high molecular weight HA and a HA oligosaccharide preparation with HA fragments < 
10 kDa were used as controls. The expression of two HA receptors, namely CD44 and 
RHAMM, was determined by Western Blot and flow cytometric analyses. 
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6.2. Materials and methods 
6.2.1. Cell culture conditions and storage 
Immortalized human microvascular endothelial cells (HMEC-1, kindly provided by Prof. 
Dr. J. Heilmann) were grown in 75-cm² culture flasks (Sarstedt, Nürnbrecht, Germany) in 
Dulbecco´s Modified Eagle Medium (DMEM, Sigma-Aldrich, Munich, Germany) 
containing 15 % fetal calf serum (FCS, Biochrom, Berlin, Germany) and 2 mM L-
glutamine (Biochrom, Berlin, Germany). The cells were cultured in a water-saturated 
atmosphere of 95 % air and 5 % CO2 at 37 °C and were serially passaged following 
trypsination using trypsin (0.05 %)/EDTA (0.02 %) solution. For a detailed 
characterization of the cell see Ades et al. (Ades et al., 1992).  
For long term storage, confluent cells were detached from the bottom of the culture flask 
by trypsination, followed by trypsin inactivation of adding fresh medium, containing 
serum. Cells were counted in a Casy® 1 TTC cell counter (Schärfe Systems, Reutlingen, 
Germany), then centrifuged at 1000 g for 5 min and re-suspended in freezing medium 
(DMEM, 15 % FCS, 2 mM L-glutamine, 10 % DMSO) to a final cell density of 1 · 10
6
 
cells/mL. The suspension was split into aliquots of 1 mL and cooled down slowly for the 
storage in liquid nitrogen. For revival an aliquot of frozen cells was quickly thawed and 
diluted with 25 mL of fresh medium. After attachment of the cells to the bottom of the 
culture flask, medium was exchanged with fresh medium to remove residual DMSO. 
 
6.2.2. Preparation of cell lysates for SDS-PAGE/Western Blot 
Confluent cells in a 75-cm² culture flask were trypsinized and washed 3 times with PBS 
(800 g, 5 min). The pellet was re-suspended in 5 x the pellet volume of PBS, frozen in 
liquid nitrogen and thawed at room temperature. The freezing and thawing cycle was 
repeated 10 times to completely disrupt the cells. The protein content of the lysates was 
determined by the Bradford assay. For SDS-PAGE/Western Blot, 10 µg of protein per 
band were applied to the gel. 
 
6.2.3. SDS-PAGE and Western Blot analysis 
Electrophoresis and Western Blot analysis were performed as described in Chapter 3. The 
primary antibodies were anti human CD44 rabbit monoclonal antibody (1:5000) and anti 
human CD168/RHAMM rabbit monoclonal antibody (1:5000) (both from Epitomics Inc., 
 Materials and methods 
 - 74 - 
Burlingame, USA). As secondary antibody, donkey anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology, Santa Cruz, USA) was used. 
 
6.2.4. Hyaluronan receptor detection by flow cytometry  
For further characterization of the hyaluronan receptor expression in the used cell line, a 
flow cytometric assay (FACS) was performed. Confluent HMEC-1 cells were trypsinized, 
suspended in PBS and centrifuged at 500 g for 5 min. After re-suspension in PBS, 
containing 10 % FCS and cell counting, a cell density of 1 – 2 · 106 /mL was adjusted with 
PBS/FCS. The cell suspension was split into aliquots of 500 µL and the primary antibody 
was added to an appropriate dilution (CD44: 1:30, RHAMM: 1:500). Following 1 h of 
incubation, cells were washed 3 times with PBS (400 g, 5 min, 4 °C) and then re-
suspended in a solution of 3 % BSA in PBS, containing the secondary antibody at a 
dilution of 1:250 (goat-anti-rabbit IgG, phycoerythrin conjugated from Rockland Inc., 
Gilbertsville, USA). After 1 h of incubation in the dark, cells were washed again twice 
with PBS, re-suspended in 500 µL of 3 % BSA/ PBS and measured in a FacsCalibur™ 
(Becton Dickinson, Heidelberg Germany). Instrument settings were: FSC: E-1, SSC: 350, 
Fl-2, flow high. Raw data were averaged with the WinMDI 2.9 software and then exported 
to SigmaPlot™ 11.0. 
 
6.2.5. Preparation of different hyaluronan digestion mixtures 
Hyaluronan digestion mixtures were prepared by incubation of HA from rooster comb 
(Sigma-Aldrich, Munich, Germany) with BTH, rhHyal-1 and human platelet membrane 
preparation, respectively. Incubation mixtures contained 8 mL of McIlvaine´s buffer (pH 
4.0 for rhHyal-1 and platelets, pH 5 for BTH), 2 mL of BSA solution (0.2 mg/mL), 2 mL 
of HA solution (5 mg/mL) and 3 mL of enzyme sample. Final enzymatic activities for 
rhHyal-1 and BTH were 0.28 U and 0.033 U, respectively. The mixtures were incubated at 
37 °C for 48 h, then dialyzed against 0.1 M ammonium acetate using a SpectraPor MWCO 
500 membrane and lyophilized. Characterization of the HA digestions was achieved by 
polyacrylamide gel electrophoresis as described in Chapter 3 for longer HA fragments but 
with 15 % PAA gels and by High Performance Anion Exchange Chromatography with 
pulsed amperometric detection (HPAEC-PAD)
2
 for fragments of smaller chain length. 
                                                 
2
 M. Rothenhöfer, personal communication 
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6.2.6. Crystal violet assay for proliferation studies 
For endothelial cell proliferation studies, the crystal violet assay was performed as 
described by Bernhardt et al. (Bernhardt et al., 1992). 100 µL of cell suspension were 
seeded in 96-well flat-bottomed microtiter plates (Greiner, Frickenhausen, Germany) at a 
density of about 15 cells/ microscopic field (magnification: 320 x). The plates were 
incubated at 37 °C (water-saturated atmosphere, 5 % CO2) for 24 h before adding the HA 
digests. Therefor the lyophilisates were solved in water to a concentration of 10 mg/mL 
and sterile filtered, mixed with fresh medium and 100 µL were added to the cells. Final 
concentrations of the hyaluronan digests were: 5, 10, 30, 50 and 100 µg/mL. As controls 
high molecular weight HA (nHA) from rooster comb and HA oligosaccharides with an 
average molecular weight < 10 kDa (o-HA, Hyalo-Oligo
®
 was a kind gift from Kewpie 
Corporation, Tokyo, Japan) were used. On every plate two rows served as growth controls 
where no HA was added and one row (n = 8) was used per HA concentration. 
After various periods of incubation, the culture medium was shaken off the plates and the 
cells were fixed with a 1 % solution of glutardialdehyde in PBS and stored at 4 °C. At the 
end of the experiment all plates were stained with a 0.02 % aqueous solution of crystal 
violet simultaneously. After washing the plates with water and dissolving bound stain with 
180 µL/well of 70 % ethanol, absorbance was measured at 580 nm using a Tecan Genios 
Pro microtiter plate reader (Tecan, Crailsheim, Germany) with XFluor Genios Pro software 
version V.4.55. 
Results are presented as plots of absorbance versus time of incubation using SigmaPlot 
version 11.0. 
 
6.3. Results and discussion 
6.3.1. Expression of the hyaluronan receptors CD44 and RHAMM by HMEC-1 cells 
6.3.1.1. Western Blot analysis 
Western Blot analysis of HMEC-1 lysate for CD44 and RHAMM revealed that only 
RHAMM is expressed. A MCF-7 cell lysate served as positive control for RHAMM 
immunodetection (Product data sheet from Epitomics). For CD44 control, HT-29 cells 
were used, because these cells were previously shown to express the receptor isoform 
CD44 E (Dougherty et al., 1994). However, the used primary antibody was possibly 
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unsuitable for the detection of CD44 isoforms, both in endothelial and HT-29 cells, 
because no bands were detectable in the Western Blot (data not shown). 
The other hyaluronan receptor RHAMM was detected as a single band, with a molecular 
weight of approximately 84 kDa, which was found in cell lysates of both, MCF-7 and 
HMEC-1 (Fig. 6.1). The experimentally determined molecular mass is in good agreement 
with the calculated mass of 84.1 kDa for RHAMM Class A. 
 
 
6.3.1.2. Determination of CD44 and RHAMM in endothelial cells by flow 
cytometry 
In addition to the Western Blot analysis of the HA receptors, an indirect flow cytometric 
assay was performed. In analogy to Western Blot analysis, only RHAMM expression could 
be demonstrated as shown in Fig. 6.2. As negative controls the autofluorescence of the 
cells and possible binding of the secondary antibody alone were used. The secondary 
antibody alone did not bind to the HMEC-1 cells, thus the shift in fluorescence intensity 
after incubating with RHAMM antibody is due to binding of the primary antibody to the 
HA receptor. We were not able to show CD44 expression in HMEC-1 cells, neither by 
Western Blot analysis, nor in the FACS assay, whereas other authors reported on CD44 
expression on the surface of these cells (Trochon et al., 1996; Xu et al., 1994). CD44 
expression was suggested to be involved in endothelial cell proliferation, migration and 
angiogenesis (Savani et al., 2001; Trochon et al., 1996). 
Fig. 6.1: Immunodetection of RHAMM in MCF-7 (lane A) 
and HMEC-1 (lane B) cell lysates. RHAMM monoclonal 
antibody was used as primary antibody, donkey-anti-rabbit 
IgG, peroxidase conjugated was used as secondary antibody 
and detection was achieved by ECL. 
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Fig. 6.2: Flow cytometric analysis of hyaluronan receptors in human endothelial cells. Primary 
antibodies were monoclonal antibodies against CD44 and RHAMM, respectively. The secondary 
antibody was phycoerythrin-conjugated goat-anti-rabbit IgG.  
 
6.3.2. Characterization of the different hyaluronan digests 
The lyophilized hyaluronan digests were analyzed with respect to the sizes of the 
fragments generated through enzymatic cleavage by the different hyaluronidases. 
Fragments with a higher molecular weight were analyzed by polyacrylamide gel 
electrophoresis. In Fig. 6.3 the gel and the corresponding densitometric scan are depicted. 
Digestion of HA by human platelet membranes ended with fragments of approximately 10 
kDa in size. rhHyal-1 degraded HA from rooster comb to fragments smaller than 20 kDa, 
but the smallest digestion products could not be determined with electrophoresis, because 
the detection limit with 15 % PAA gels was about 10 kDa. Hence, degradation products 
from rhHyal-1 activity had to be determined with another analytical method. 
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Fig. 6.3: Polyacrylamide gel electrophoresis and corresponding densitometric scans of lyophilized 
HA digests resulting from incubations of HA from rooster comb (lane A) with 0.03 U BTH (lane 
B), 0.28 U rhHyal-1 (lane C) and 0.2 mg proteins from human platelet membranes (lane D) 
Obviously, BTH degrades HA to fragments, which are smaller than the detection limit of 
the electrophoretic method. Therefore a method developed by M. Rothenhöfer in our 
workgroup, HPAEC-PAD, was used to assess the sizes of low molecular weight fragments 
generated by BTH and rhHyal-1, respectively. The main product of HA degradation by 
BTH was the tetrasaccharide (n2) (Fig. 6.4 A), which has already been identified as the 
major and smallest hydrolysis product by means of ion-spray mass spectrometry (Takagaki 
et al., 1994) and capillary zone electrophoresis (CZE) (Hofinger et al., 2007). For rhHyal-1 
the reaction products vary between the tetrasaccharide (n2) (Fig. 6.4 B) and HA fragments 
of molecular weights up to ~ 20 kDa. 
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Fig. 6.4: HPAEC-PAD
3
 of lyophilized HA digests resulting from incubation of HA from rooster 
comb with BTH (A) and rhHyal-1 (B), respectively. n represents 1 HA disaccharide unit, e.g. the 
tetrasaccharide is named n2. 
 
6.3.3. Investigations of the effect of HA digests on the proliferation of human 
endothelial cells 
To investigate, if there is any effect on the proliferation of human microvascular 
endothelial cells by adding the different hyaluronan digests, a proliferation assay in the 96-
well plate format was performed. Experiments were run over 162 h of incubation and cell 
densities in the wells were measured by crystal violet staining.  
As illustrated by Fig. 6.5, we could hardly detect any effect on endothelial cell 
proliferation, neither by n-HA, nor by hyaluronan digests containing fragments of sizes 
suggested to be involved in cell signalling or angiogenesis. Possibly, these results correlate 
with the absence of CD44 on the surface of the used cells, as Lokeshwar et al. and Trochon 
et al. showed that blocking of CD44 with antibodies resulted in inhibited endothelial cell 
proliferation (Lokeshwar et al., 1996; Trochon et al., 1996). Savani et al. additionally 
investigated the effect of a RHAMM antibody and found that the CD44- but not the 
RHAMM antibody was able to inhibit EC proliferation (Savani et al., 2001). Only the HA 
digest resulting from incubation with human platelet membranes showed a slight dose-
dependent inhibition of cell proliferation. This effect may be due to remaining platelet 
membrane components in the HA digest preparation. 
                                                 
3
 M. Rothenhöfer, personal communication 
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Fig. 6.5: Proliferation curves of human endothelial cells after addition of different concentrations 
of digests of high molecular weight HA (n-HA) from rooster comb with BTH, rhHyal-1 and human 
platelet membranes. Proliferation curves after addition of different concentrations of HA 
oligosaccharides (o-HA, molecular mass < 10 kDa) served as second control. Growth curves were 
determined with a kinetic microassay based on crystal violet staining. 
 
6.4. Summary and conclusion 
Different lyophilized hyaluronan digests were prepared in order to investigate their effect 
on human microvascular endothelial cell proliferation by a kinetic proliferation assay 
based on crystal violet staining. The fragments produced by BTH, rhHyal-1 and human 
platelet-derived Hyal-2 were characterized with respect to their size distribution by 
polyacrylamide gel electrophoresis with combined alcian blue silver staining and HPAEC-
PAD, respectively. The main product of BTH degradation was the tetrasaccharide. This is 
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in accordance with previously reported results (Hofinger et al., 2007; Takagaki et al., 
1994). Fragments generated by rhHyal-1 varied between the tetrasaccharide and 
oligosaccharides with molecular weights of ~ 20 kDa. Degradation of HA by incubation 
with human platelet membrane preparations containing Hyal-2 gave fragments of 
molecular weights > 10 kDa or 25 disaccharide units. Fragments which have been 
suggested to induce cell proliferation and angiogenesis were detectable in all lyophilized 
HA digests. High molecular weight HA and a HA preparation with a molecular weight of < 
10 kDa were used as controls. 
To determine the expression of the hyaluronan receptors CD44 and RHAMM, 
immunodetection methods were applied. Only RHAMM expression could be verified in 
the used HMEC-1 cells. There was no evidence for CD44, although this receptor was 
reported to be present in HMEC-1 by Trochon et al. and Xu et al. (Trochon et al., 1996; Xu 
et al., 1994). This indicates that either the antibody used in this study was not suitable to 
detect the CD44 isoform in the cells, or the cells did not express the HA receptor. The 
latter is supported by the results from the proliferation assay. 
We could hardly determine any effect on HMEC-1 proliferation by adding the different 
HA digests at any concentration over an incubation period of 162 h. The absence of an 
effect can be explained by the lack of CD44 expression on the surface of the HMEC-1 
cells, as the interaction between HA fragments and CD44 seems to be essential for 
inducing proliferation (Nandi et al., 2000; Savani et al., 2001; Slevin et al., 1998; Trochon 
et al., 1996). On the contrary, Gao et al. proposed that a RHAMM mediated signal pathway 
and not CD44 is responsible for stimulation of proliferation by HA oligosaccharides (Gao 
et al., 2008). As these authors used a porcine iliac vascular endothelial cell line, species-
dependent differences in o-HA mediated cell proliferation cannot be ruled out, but this 
suggestion needs to be verified by further investigations. 
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7.1. Introduction 
Streptococcus pneumoniae is a bacterial respiratory pathogen and an important cause of 
many diseases like pneumonia, meningitis, otitis media and sinusitis (Boulnois, 1992). 
The gram-positive, alpha-hemolytic bacterium is a common mucosal resident in the 
nasopharynx, especially in young children (Marchisio et al., 2002). Recent studies show a 
worrying increase in drug resistant strains of S. pneumoniae (DRSP) (Nuermberger and 
Bishai, 2004). Hence, new selective antibiotics or vaccines would be useful tools in the 
treatment of DRSP infections. 
The bacterium produces several virulence factors, such as the capsule, pneumococcal 
surface proteins A and C, pneumolysin and hyaluronate lyase (SpnHyl). The bacterial 
hyaluronidase could serve as a target for new “antibacterial” agents (Kadioglu et al., 2008) 
to inhibit the spreading of the bacteria in the tissue and to enhance the efficacy of co-
administered antibiotics. 
SpnHyl acts as a spreading factor for the bacterium by cleaving hyaluronan in the 
extracellular matrix of connective tissues in the host through an enzymatic ß-elimination 
process. In S. pneumoniae cultures, the enzyme was detected in both the culture medium 
and the cell-associated fractions. This suggests that a portion of SpnHyl is released by the 
bacterium during infection to facilitate bacterial invasion (Berry et al., 1994). After 
successful crystallization and X-ray analyses by Jedrzejas et al. (Jedrzejas et al., 1998a; 
Jedrzejas et al., 1998b), recent structural studies deal with the mechanism of hyaluronan 
degradation by SpnHyl. The enzyme structure contains two domains: one built mostly 
from helices, which form the catalytic domain with a cleft responsible for HA binding and 
degradation, and the C-terminal domain consisting almost entirely of ß-sheets (Li et al., 
2000; Ponnuraj and Jedrzejas, 2000). The knowledge of the structure and the suggested 
mechanism of action of the enzyme render the application of computer-aided methods in 
search of possible inhibitors. However, there are just a few rather weak inhibitors of 
SpnHyl known so far, such as L-ascorbic acid 6-hexadecanoate with an IC50 value of 100 
µM (Botzki et al., 2004) or a 2-phenylindole (1-decyl-2-(4-sulfamoyloxyphenyl)-1H-
indol-6-yl sulfamate) with an IC50-value of > 100 µM (Rigden et al., 2006) (Fig. 7.1). 
These molecules are non-selective and not drug-like. Thus, in cooperation with Origenis 
GmbH (Martinsried, Germany) new more drug-like molecules were designed, synthesized 
in a multi-component reaction approach and screened for inhibitory activity on purified 
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SpnHyl and hyaluronate lyase from S. agalactiae (SagHyal4755), respectively. Both 
enzymes show a sequence identity of 53 % (Rigden et al., 2006). 
 
Fig. 7.1: Structures of known inhibitors of SpnHyl. 1: L-ascorbic acid 6-hexadecanoate; 2: 1-
decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl sulfamate  
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7.2. Materials and methods 
7.2.1. Small scale expression of S. pneumoniae hyaluronate lyase 
SpnHyl-6-His was expressed in E. coli strain BL21 (DE3) as described before (Jedrzejas 
et al., 1998b). In brief, a transformed E. coli cell colony was inoculated into 200 mL of LB 
medium supplemented with 100 µg/mL ampicillin and incubated at 37 °C on an incubator-
shaker overnight. The protein was then induced by addition of isopropyl-ß-D-1-
thiogalactopyranoside (IPTG, Sigma-Aldrich, Munich, Germany) and growth was 
continued for another 3 h. The cells were harvested by centrifugation at 6000 rpm at 4 °C 
for 10 min. The resulting cell pellet was re-suspended in McIlvaine´s buffer pH 5.0, 
supplemented with 20 % of glycerol and frozen at -80 °C. After thawing on ice, the 
suspension was again centrifuged and the pellet re-suspended in McIlvaine´s buffer pH 
6.0. The sample was sonicated for 5 x 20 s with 1 min intervals on ice and the resulting 
cell lysate was centrifuged at 15000 rpm at 4 °C for 30 min. The supernatant was then 
used for activity measurements, SDS-PAGE and Western Blot analysis. 
 
7.2.2. SDS-PAGE and Western Blot analysis 
Gel electrophoresis and Western Blot analysis were performed as described in Chapter 3. 
As primary antibody anti-6-His (Sigma-Aldrich, Munich, Germany) at a dilution of 
1:5000 was used. The secondary antibody was goat anti-mouse IgG (Fc specific), 
peroxidase-conjugated (Sigma-Aldrich, Munich, Germany) at a dilution of 1:1000. 
 
7.2.3. Purification of SpnHyl with Ni-Sepharose™ 6 FF 
Ca. 10 g of frozen cell pellets from large scale expression performed by Christian Textor 
from our laboratories in cooperation with the Institute of Biotechnology (Prof. Dr. R. 
Rudolph) at the Martin-Luther University Halle-Wittenberg (Germany), were thawed on 
ice and centrifuged at 6000 rpm at 4 °C for 10 min. The pellet was re-suspended in 50 mL 
of binding buffer (20 mM Na2HPO4, 0.5 M NaCl, 20 mM imidazole, pH 7.4), 
supplemented with an EDTA-free protease inhibitor cocktail (Sigma-Aldrich, Munich, 
Germany) following sonication as described in 7.2.1. The cell lysate was centrifuged at 
15000 rpm at 4 °C for 30 min and the supernatant was used for purification with Ni 
Sepharose™ 6 FF (GE Healthcare, Munich, Germany). 
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For purification Ni Sepharose was washed with 5 x Sepharose volume of water by gentle 
shaking for 15 min. Ni Sepharose was then sedimented by centrifugation at 1000 g for 5 
min, the supernatant was discarded. The washing and centrifugation procedure was 
repeated with 5 x Sepharose volume of binding buffer. After discarding the supernatant a 
50 % slurry was made by adding an appropriate volume of binding buffer to the Ni 
Sepharose. This slurry was used for sample binding. One slurry volume of cell lysate was 
added and binding of SpnHyl-6-His was allowed for 1 h under gentle shaking at room 
temperature. Afterwards the suspension was centrifuged at 1000 g for 5 min and the 
supernatant was again discarded. The sedimented Ni Sepharose was washed 3 times with 
5 x volume of binding buffer and the supernatants were collected. The following elution 
steps were performed by adding 3 times 2 x Sepharose volume elution buffer (20 mM 
Na2HPO4, 0.5 M NaCl, 0.5 M imidazole, pH 7.4) and collecting the supernatants. All 
samples resulting from the washing and elution steps were analyzed by SDS-PAGE. The 
elution fractions were desalted with PD-10 columns (purchased from Sigma-Aldrich, 
Munich, Germany); their protein content was determined by the method of Bradford 
(Bradford, 1976) using the Bio-Rad protein assay (Bio-Rad, Munich, Germany) following 
the manufacturer´s instructions for the standard microtiter plate assay and hyaluronidase 
activity was determined with the colorimetric assay (see below). 
 
7.2.4. Colorimetric hyaluronidase activity assay 
Hyaluronidase activity was determined by a colorimetric assay (Morgan-Elson reaction) 
as described elsewhere in detail (Muckenschnabel et al., 1998). Thereby N-acetyl-D-
glucosamine (NAG) (Sigma-Aldrich, Munich, Germany) at the reducing end of sugars 
generated from hyaluronan was determined according to the method of Reissig et al. 
(Reissig et al., 1955). Enzymatic activity was quantified by comparing the absorbance of 
the samples with the absorbance of standards containing known amounts of NAG, which 
were treated exactly like the samples. According to the International Union of 
Biochemistry 1 unit (U) of hyaluronidase is defined as the enzymatic activity catalyzing 
the liberation of 1 μmol NAG at the reducing ends of sugars per min under specified 
conditions. 
The incubation mixtures contained 200 µL of McIlvaine´s buffer pH 6.0, 50 µL of H2O, 
50 µL of BSA solution (0.2 mg/mL), 50 µL of hyaluronan solution (5 mg/mL) and 50 µL 
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of elution fraction. The samples were incubated at 37 °C for 30 min followed by adding 
110 µL of alkaline borate solution and heating at 100 °C for 4.5 min to stop the enzymatic 
reaction. After cooling on ice for 2 min, 1.25 mL of p-dimethylaminobenzaldehyde were 
added and the color was allowed to develop for 20 min at 37 °C. The absorbance of the 
samples and standards was measured at 586 nm using a Cary 100 UV-Vis 
spectrophotometer (Varian, Darmstadt, Germany). 
 
7.2.5. Turbidimetric hyaluronidase activity assay for screening 
The turbidimetric hyaluronidase assay was performed according to Di Ferrante (Di 
Ferrante, 1956) with modifications for the 96 well plate format.  
The incubation mixtures contained 30 µL of McIlvaine´s buffer pH 5.0, 8 µL of BSA 
solution (0.2 mg/mL), 8 µL of HA solution (2 mg/mL), 9 µL of H2O, 10 µL of inhibitor 
solution (1.5 mM in 30 % DMSO) and 10 µL of enzyme solution (10 IE in 0.2 mg/mL 
BSA solution) per well. Reference wells contained the corresponding solvent instead of 
the inhibitor solution and for the preparation of reference A 0.2 mg/mL BSA solution was 
used instead of enzyme. As some compounds from the multi-component reactions were 
colored, blank wells were prepared for every compound to exclude false positive values. 
Blank wells contained H2O instead of HA in the reaction mixture and BSA instead of 
enzyme. Vcpal served as reference inhibitor. After incubation of the MTPs at 37 °C for 1 
h, 200 µL of 2.5 % cetyltrimethylammonium bromide (CTAB) solution (2.5 % CTAB in 
0.5 N NaOH) were added to each well to precipitate residual high molecular weight 
hyaluronan. Turbidity was allowed to develop for 20 min at RT. The optical density was 
then measured at 580 nm using a Tecan Genios Pro microtiter plate reader (Tecan, 
Crailsheim, Germany) with XFluor Genios Pro software version V.4.55. The values of the 
blank wells were subtracted from the OD values of samples and references before 
calculating relative activity of SpnHyl in presence of inhibitor using the following 
equation: 
               
                 
               
 
Eq. 7.1 
The values for relative enzyme activity given in the result section are mean values ± 
SEM (standard error of the mean) of duplicates. 
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For determination of the IC50 value, the residual enzymatic activities after incubation with 
various concentrations of inhibitor were plotted against the logarithm of the inhibitor 
concentration. The IC50 value was calculated by curve fitting of experimental data with 
SigmaPlot 11.0 (simple ligand binding, sigmoidal dose response). 
 
7.3. Results and discussion 
7.3.1. Small scale expression of S. pneumoniae hyaluronate lyase 
Expression of SpnHyl was accomplished in BL21 cells and isolation of the protein was 
performed as described in the materials and method section. Enzymatic hyaluronidase 
activity in the unpurified sample was investigated using the turbidimetric assay and it was 
measureable after 15 min of incubation. Thereafter, expression of SpnHyl was verified by 
SDS-PAGE and Western Blot analysis. SDS-PAGE of 10 µg of unpurified protein 
revealed a prominent protein band at 84 kDa, which closely corresponds to the expected 
molecular weight of 83 kDa (Jedrzejas et al., 1998b). This protein band was then shown to 
be SpnHyl-6-His in the Western Blot analysis using an anti-6-His primary antibody (Fig. 
7.2). 
 
Fig. 7.2: SDS-PAGE (left) and Western Blot (right) analysis of isolated unpurified protein from 
small scale SpnHyl expression experiment (lane B). Non-transfected BL21 cells served as negative 
control (lane A). SDS-PAGE was stained with Coomassie brilliant blue, primary antibody for 
Western Blotting was an anti-6-His antibody; secondary antibody was a HRP-conjugated goat-
anti-mouse antibody. Immunodetection was achieved with ECL. 
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7.3.2. Purification and characterization of SpnHyl after large scale expression 
After the successful expression of enzymatically active SpnHyl in the small scale format, 
the protein expression was scaled up
4
. The supernatant of the lysed cells was purified 
using Ni-Sepharose and the resulting elution fractions were analyzed with respect to 
protein content, purity and enzymatic activity. As shown in Fig. 7.3, elution fraction II 
appeared to have a satisfying purity, so the screening of small molecule inhibitors was 
performed using only elution fraction II after determination of its specific activity. 
 
 
Fig. 7.3: Purification of SpnHyl from large scale expression. 
Lane A: unpurified supernatant from cell lysis; lane B: 
elution fraction I; lane C: elution fraction II. 20 µL of sample 
were applied to the SDS-gel and staining was accomplished 
with Coomassie brilliant blue. 
 
After purification and desalting, the protein content of the elution fractions was 
determined using the method of Bradford (Bradford, 1976) in the microtiter plate format. 
Elution fractions I and II contained 13.5 and 5.5 µg/mL protein, respectively. Enzymatic 
activity was then measured using the colorimetric hyaluronidase assay and specific 
activity in U/mg was calculated by dividing enzymatic activity and protein content (Tab. 
7.1). 
Tab. 7.1: enzymatic and specific activity of SpnHyl in the elution fractions as determined with the 
colorimetric assay. Results are presented as mean ± SEM from two independent experiments. 
elution fraction enzymatic activity (mU/mL) specific activity (U/mg) 
I 63.5 ± 3.9 4.7 ± 0.3 
II 21.3 ± 1.7 3.9 ± 0.3 
 
7.3.3. Screening of small molecules for inhibition of SpnHyl 
The 96-deep-well plates from the multicomponent reaction approach were provided by C. 
Textor from our workgroup. Each substance was tested in duplicates at an assumed final 
concentration of 200 µM for inhibition of SpnHyl at a final enzymatic activity of 0.1 mU. 
                                                 
4
 C. Textor, personal communication 
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After performing the turbidimetric assay, deep-well plates were controlled for the presence 
of the desired molecules by means of mass spectrometry, and screening hits were 
summarized. Results of each plate shown in Fig. 7.4 are from two independent 
experiments ± SEM. Residual SpnHyl activity after incubation with the generated 
molecules were compared to the results obtained with SagHyal4755 for estimating the 
selectivity. A screening hit was defined as generated molecule with an inhibitory activity 
of ≥ 50 %.  
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Fig. 7.4: Results of screening for inhibition of SpnHyl by small molecules from a multicomponent synthesis approach. Each chart corresponds to one 96-deep-
well plate. ○ wells in which the target compounds could not be detected; ● wells in which the desired product was generated as confirmed by mass 
spectrometry; ● screening hits; ● results of the screening for inhibition of SagHyal4755, wells with generated product 
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Four molecules out of a total of 1352 screened molecules were identified as “hits”, 
corresponding to a hit rate of 0.3 %. The structures of the screening hits are depicted in 
Fig. 7.5. 
 
Fig. 7.5: Structures of the four screening hits with the highest inhibitory activity against SpnHyl. 
All identified compounds are imidazopyridines with rather space-filling substituents in 
positions 2 and 3. 
In Tab. 7.2 the inhibitory activities of the identified hits on SpnHyl are summarized and 
compared to the activities on SagHyal4755. All compounds proved to inhibit SpnHyl 
activity to a higher extent, indicating possible selectivity for this bacterial enzyme. 
Tab. 7.2: Inhibitory activities of the identified hits on SpnHyl at an assumed concentration of 200 
µM. Presented values are means ± SEM of duplicates. Activities were compared to inhibition of 
SagHyal4755
5
. 
Compound Inhibition of SpnHyl (%) ± SEM 
(assumed concentration: 200 µM) 
Inhibitory activity on SagHyal4755 
(%) (assumed concentration: 200 
µM) 
Plate 2; G5 45 ± 5 8 
Plate 15, C4 60 ± 2 18 
Plate 15, C6 82 ± 6 9 
Plate 15, C7 51 ± 5 8 
 
                                                 
5
 C. Textor, personal communication 
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After the screening for small molecule inhibitors, a purified 2-phenylindole
6
 (Fig. 7.6) 
(UR-CT-619) bearing space-filling substituents in 1- and 2-position and structurally 
resembling the identified hits, was tested for inhibition of SpnHyl activity.  
 
 
Fig. 7.6: Structure of the purified compound tested for 
inhibitory activity on SpnHyl, UR-CT-619 
 
The compound was tested in the turbidimetric assay at different concentrations in 
triplicate and the IC50 value was determined as described in the material and methods 
section (Fig. 7.7).  
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Fig. 7.7: Graph for determination 
of the IC50 value for UR-CT-619. 
Presented data are mean values ± 
SEM of triplicates.  
 
An IC50 value of 93 µM ± 1.05 was determined for inhibition of SpnHyl. To our 
knowledge this is the most potent drug-like small molecule inhibitor of SpnHyl designed 
so far. Interestingly, UR-CT-619 is even more potent as an inhibitor of SagHyal4755
7
. By 
contrast the imidazopyridines identified as hits showed selectivity towards SpnHyl. 
Therefore, these compounds have to be re-synthesized for more detailed studies on 
bacterial hyaluronidases to substantiate the results. We suspect that the apparent 
selectivity for SpnHyl is due to the missing carboxylic group in the identified molecules. 
                                                 
6
 provided by C. Textor from our workgroup 
7
 C. Textor, Personal communication 
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7.4. Summary and conclusion 
SpnHyl-6-His was successfully expressed in E. coli strain BL21 cells and purified by 
means of a Ni-Sepharose. The enzyme was then used in a screening approach to identify 
small molecules as inhibitors of SpnHyl. The compounds were synthesized by 
multicomponent reactions in the microtiter plate format. After having tested 1352 
potential inhibitors in a turbidimetric 96-well microtiter plate assay, the deep-well-plates 
were analyzed for the presence of the desired molecules and screening hits were identified. 
The screening revealed 4 hits with inhibitory activities on SpnHyl of ≥ 50 %. The most 
potent compound was identified in well C6 on plate 15, showing 82 % inhibition of 
SpnHyl at an assumed final concentration of 200 µM. All identified compounds possess a 
similar structure based on an imidazopyridine scaffold with rather space-filling 
substituents in positions 2 and 3. Moreover these hits have promising drug-like properties, 
fulfilling Lipinski´s rule of five. 
In order to substantiate the screening results, UR-CT-619, a 2-phenylindole having a 
rather similar structure compared to the identified hits was tested for inhibition of SpnHyl. 
With the turbidimetric assay, an IC50 value of 93 µM was determined and therefore UR-
CT-619 was identified as the most potent SpnHyl inhibitor reported so far.  
The inhibitory effects of the generated molecules on SpnHyl were compared to those on 
another bacterial hyaluronidase, SagHyal4755. UR-CT-619 was shown to be even more 
potent as an inhibitor of SagHyal4755, whereas all previously identified screening hits 
showed selectivity towards SpnHyl. We therefore suggest that a carboxylic group, as 
present in UR-CT-619, is important for inhibition of SagHyal4755 compared to SpnHyl. 
Additional studies with purified hit compounds have to be performed to proof inhibition of 
SpnHyl and to explore the structure-activity relationships.  
Provided that the screening hits will be confirmed as potent inhibitors of SpnHyl, 
optimized compounds might be useful to perform proof-of-concept studies on the potential 
value of hyaluronidase inhibitors as antibacterial agents. The inhibition of the spread of 
pathogenic Streptococci, particularly in the early stage of infections, may prevent the 
onset of bacterial disease. Moreover, the compounds could be valuable pharmacological 
tools in further understanding the role of the hyaluronate lyase for the bacterium. 
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Hyaluronan (hyaluronic acid, HA) and its degradation products, generated by 
hyaluronidases, are known to be involved in cell signaling, cell migration, inflammation 
and tumor invasion. But the role of hyaluronidases in physiological and pathological 
processes is relatively unclear, due to insufficient information on enzymatic properties and 
the lack of specific inhibitors as pharmacological tools. Especially hyaluronidase-2 (Hyal-
2) has been a matter of debate with respect to the degradation of hyaluronan. Therefore, 
the aim of this thesis was to investigate the catalytical Hyal-2 activity of a recombinant 
human enzyme and in blood cells.  
Recombinant human Hyal-2, expressed in DS-2 insect cells, elaborated by Edith Hofinger, 
was successfully purified to investigate enzymatic activity using two different methods. 
Viscosimetry was previously shown to be the most sensitive among the classical 
hyaluronidase assays. The isolated rhHyal-2 proved to be able to degrade hyaluronan 
within 24 h under acidic conditions (pH = 4.0). Surprisingly, a preference for HA from 
vertebrate sources (human umbilical cord, rooster comb) over HA of microbial origin was 
observed. The former was degraded faster and to an apparently higher extent than HA 
from S. zooepidemicus. By means of polyacrylamide gel electrophoresis followed by a 
combined alcian blue, silver staining protocol it became possible to estimate the size of the 
HA fragments generated by the action of rhHyal-2. The results obtained with this method 
correlated well with data from viscosimetric measurements. HA fragments, formed by the 
degradation of HA from vertebrate sources (< 15 kDa) were definitely smaller in size than 
those produced by degradation of HA from S. zooepidemicus (~ 20 kDa).  
Inspired by results published by Carol de la Motte et al., human and murine blood platelets 
were chosen to investigate native Hyal-2. Hyal-2 is the only hyaluronidase present in 
platelets, with no evidence for other hyaluronidase isoforms. Extensively washed platelets 
and platelet membrane preparations were analyzed with respect to hyaluronidase activity 
at different pH values using HA from different sources. Hyaluronan degrading activity 
could only be detected at acidic pH of 4.0. By analogy with rhHyal-2, HA from 
vertebrates was the preferred substrate of platelet-associated Hyal-2. In order to 
unambiguously exclude that, despite extensive washing of the samples, the observed 
hyaluronidase activity in platelets is due to traces of plasma Hyal-1, platelets from Hyal-2 
knock-out (KO) mice were analyzed exactly in the same way as wildtype platelets. 
Thereby, Hyal-2 activity was definitely proven in platelets, as there was no HA digestion 
after incubation with KO platelets. 
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Additionally, red blood cells (RBCs) were investigated. The presence of Hyal-2 and the 
absence of Hyal-1 were confirmed by Western Blot analysis, and erythrocytes and ghost 
membrane preparations were analyzed for Hyal-2 activity. Although HA degradation in 
the presence of RBCs was high, the enzymatic activity resulted from residual plasma 
Hyal-1. There was no hydrolytic activity upon incubation (72 h) of HA with ghost 
membrane preparations at any pH tested. The biological relevance of the relatively high 
expression of Hyal-2 in RBCs, detected immunologically, needs to be further investigated 
either with regard to the existence of a putative co-receptor or an endogenous inhibitor, 
associated with Hyal-2 in the RBC membranes. 
To gain more insight into the role of HA fragments and to explore, if platelets are capable 
of generating biologically active HA oligosaccharides, the proliferation of endothelial 
cells (EC) was examined after addition of HA digests. However, there was no effect on 
cell proliferation. As there was no evidence for expression of the HA receptor CD44 by 
these cells, it can be speculated that the presence of functional CD44 is essential for 
enhanced cell proliferation mediated by binding HA fragments. 
Hyaluronidases are also considered virulence factors of microorganism, including several 
pathogenic strains of Streptococci. Inhibitors of such hyaluronate lyases could serve as 
pharmacological tools or might be used as adjuvant in the chemotherapy of drug-resistant 
bacteria. In a screening approach, out of 1352 molecules, obtained from multicomponent 
synthesis, 4 imidazopyridines were identified as inhibitors of a bacterial lyase (SpnHyl). 
At an estimated concentration of 200 µM, the most potent compound showed 82 % 
inhibition of SpnHyl, when incubated with the reaction mixture. In addition, a structurally 
related conventionally synthesized 2-phenylindole (UR-CT-619), proved to be the most 
potent inhibitor of SpnHyl known so far. 
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1 Introduction 
Breast cancer comprises a collection of heterogeneous disease entities. Consequently, 
both, preclinical and clinical research target specific subgroups of breast cancer with the 
aim to reveal subgroup-specific therapies. Examples include the targeting of estrogen 
receptor (ER)-driven breast cancers using tamoxifen or the subgroup driven by the human 
epidermal growth factor receptor 2 (HER2), which is targeted by trastuzumab 
(Widakowich et al., 2007). However, these newer targeting strategies are of no benefit for 
a significant group of women (15 % of all types of breast cancer), who have breast cancers 
that fail to express ERs and progesterone receptors (PRs) and that do not overexpress 
HER2. This type of cancer is in the so-called receptor-negative or triple-negative (TN) 
category. Because of the absence of specific treatment options, triple-negative cancers are 
managed with standard treatment associated with a high rate of local and systemic relapse.  
Histologically and transcriptionally, TN breast cancers have many similarities to breast 
cancer susceptibility gene 1 (BRCA1) associated breast cancers, which suggests that 
dysfunction in BRCA1 or related pathways occurs in this subset of cancers (Cleator et al., 
2007). A lack of BRCA1 results in DNA repair by non-conservative, potentially 
mutagenic mechanisms, and therefore, leads to genomic instability and cancer 
predisposition (Turner et al., 2004). There is increasing evidence that BCRA1 related 
cancers confer sensitivity to particular systemic agents such as platinum-based drugs (e.g. 
cisplatin), which bring about interstrand cross-links (Byrski et al., 2009). 
Due to severe toxic side effects and the development of resistance against cisplatin, new 
analogues have been developed. One of these is lobaplatin (Fig. 1), a platinum drug of the 
third generation. In previous in vitro studies, lobaplatin exhibited activity against various 
cancer cell lines with an incomplete cross-resistance to cisplatin (McKeage, 2001). In 
phase I and II clinical trials, lobaplatin displayed no nephro-, neuro- or ototoxicity, but the 
dose limiting toxicity was short-lasting thrombocytopenia, which is manageable (Gietema 
et al., 1995). In the following in vitro studies, the efficacy of lobaplatin against triple-
negative breast cancer cells was investigated. 
 
Fig. 1: Structure of the third-generation platinum drug lobaplatin,  
containing stably coordinated 1,2-bis(aminomethyl)cyclo-butane 
and lactic acid as leaving group.  
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2 Materials and methods 
2.1 Platinum drugs 
Lobaplatin was kindly provided by Aeterna Zentaris (Frankfurt, Germany), cisplatin, 
carboplatin, doxorubicin, tamoxifen, vinblastin and fulvestrant were purchased from 
Sigma-Aldrich (Munich, Germany). 
 
2.2 Cell lines and culture conditions 
Five human breast cancer cell lines were investigated.. MCF-7, T-47-D and MDA-MB-
231 were obtained from the American Type Culture Collection (ATCC; Rockville, USA), 
HCC-1937 and HCC-1809 were kindly provided by Dr. Jörg Engel, Frauenklinik, 
University of Würzburg. The triple-negative cell lines HCC-1937, HCC-1806 and the ER-
negative MDA-MB-231 were cultured in RPMI-1640 medium (Sigma-Aldrich, Munich, 
Germany), containing 5 % FCS. The ER- and PR-positive cell line T-47-D was cultured in 
RPMI-1640 medium, supplemented with 5 % FCS and 10 µg/mL of insulin. The estrogen-
sensitive cell line MCF-7 was maintained in RPMI-1640, supplemented with 5 % FCS and 
1 nM estradiol. All cells were grown in a water saturated atmosphere (95 % air/5 % CO2) 
and serially passaged following trypsination with 0.05 % trypsin/0.02 % EDTA (Roche 
Diagnostics, Mannheim, Germany). 
 
2.3 Subcutaneous injection of HCC-1806 and -1937 cells and histology 
Nude mice, housed under specified pathogen free (SPF) conditions in the central animal 
facility of the University of Regensburg, were used to establish and characterize 
subcutaneous HCC-1806 and -1937 tumors. The mice were kept in type III cages from 
TecniplastTM (Hohenpeißenberg, Germany) at a 12 hours light/dark cycle, 26 °C and 70 
% relative humidity. Animals took food (Ssniff, Soest, Germany) and water (autoclaved 
tap water) ad libitum. 
For subcutaneous tumor cell implantation, cells were detached from the culture flask with 
trypsin/EDTA and FCS-free RPMI 1640. After a subsequent washing step, cells were re-
suspended with serum-free RPMI 1640 and 1·10
7
 cells (100 - 150 μL cell suspension) 
were injected under the thoracic dermis of nude mice. Tumor progression as well as body 
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weight was monitored once weekly (all animals were individually identifiable due to 
tattooed pads). 
Excised tumor tissue was fixed for at least three days in Bouin´s solution (300 mL 
aqueous saturated picric acid, 100 mL formaldehyde and 20 mL glacial acetic acid) and 
embedded in paraffin by a standard procedure (cf. section 2.3.9.1 in (Müller, 2007)). 
Sections of 6 μm were cut by a Leica RM2255 microtome (Leica, Bensheim, Germany), 
transferred to SuperFrost plus microscope slides followed by deparaffinization using 
xylene and re-hydration in a descending alcohol series. Subsequently, the samples were 
stained by the procedure of Masson-Goldner (MG). Masson-Goldner (Jerusalem’s 
modification): Weigert’s iron-haematein (45 s), rinsing (H2O demin), running tap water 
(10 min), differentiation with 200 mL of H2O demin + 20 mL of 2 M aq. hydrochloric acid 
(15 s), running tap water (10 min), rinsing (H2O demin), 0.5 % aq. phosphotungstic acid  
(15 s), running H2O demin (10 min), acid fuchsine-Ponceau (30 s), 1 % aq. acetic acid (3 
× immersion), phosphoric acid-Orange G (10 s), 1% aq. acetic acid (3 × immersion), 0.2 
% light green (3.5 min), 1 % aq. acetic acid (3 × immersion), 96% aq. ethanol (2 × 3 min), 
100 % ethanol (2 × 3 min), 100 % xylene (3 min). Entellan (Merck) was used for 
covering. 
 
2.4 Chemosensitivity assay based on crystal violet staining 
The chemosensitivity assay was performed according to Bernhardt et al. (Bernhardt et al., 
1992). In brief, 100 µL/well of cell suspension were seeded in transparent 96-well plates 
(Greiner, Frickenhausen, Germany) to a density of approximately 15 cells/microscopic 
field (magnification 320 x). After 24 h of incubation at 37 °C (water saturated atmosphere; 
5 % CO2), medium was carefully removed by suction and replaced by 200 µL of fresh 
medium containing various increasing concentrations of the platinum compounds. On 
every plate, two rows (16 wells) contained only solvent as control and two rows were used 
for the incubation with each concentration. Drugs were added as 1000-fold concentrated 
stock solutions. Approximately every 24 hours cells from a plate were fixed with 
glutardialdehyde (Merck, Darmstadt, Germany) and stored in a refrigerator. At the end of 
the experiment the cells were stained with 0.02 % crystal violet (Serva, Heidelberg, 
Germany) simultaneously. Plates were rinsed with water to remove excess dye, and cell-
bound crystal violet was extracted with 70 % ethanol for three hours under shaking. 
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Subsequently, absorbance was measured at 578 nm using a Biotek 309 Autoreader 
(Tecnomara, Fernwald, Germany). Absorbance values were transformed into corrected 
T/C values expressing the net growth of the treated cells, relative to the growth of the 
solvent control; according to T/Ccorr (%) = 100 · (T – C0)/(C – C0), where T is the 
absorbance of the treated cells, C the absorbance of the controls and C0 the absorbance of 
the cells at the time, when drug was added. T/Ccorr values at the various time points were 
plotted against the incubation time using SigmaPlot version 11.0. In Fig. 2 a diagrammatic 
representation of typical data obtained with the crystal violet assay is depicted. The 
correction for the initial cell number allows discrimination between cytostatic and 
cytocidal drug action. 
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Fig. 2: Schematic diagram illustrating the in 
vitro response of cells to chemotherapeutics. 
1: the population recovers after initial 
damage (cytotoxic drug effect), 2: cell 
proliferation is inhibited (cytostatic drug 
effect), 3: disintegration of the cells 
(cytocidal drug effect)  
 
 
3 Results and discussion 
3.1 Chemosensitivity of triple negative breast cancer cells  
The potential activity of lobaplatin against triple-negative breast cancer was investigated. 
Cisplatin and carboplatin were used as standard platinum drugs to compare the 
chemosensitivities of the different breast cancer cell types using the kinetic crystal violet 
assay. 
2 
1 
3 
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The human triple-negative breast cancer cell lines were about 10-fold more sensitive 
against the platinum drugs as the other cell lines tested. As expected, MDA-MB-231 cells 
turned out to be the most resistant against the platinum compounds. This cell line was 
previously shown to be insensitive against cisplatin (Bernhardt et al., 1992; Zhou et al., 
2011) at therapeutically relevant concentrations. 
In Fig. 3 the results of the chemosensitivity assay are shown. For cisplatin and lobaplatin a 
cytotoxic effect against HCC-1806 and HCC-1937 was observed at a concentration of 0.3 
μM, whereas in case of the other cell lines a concentration of 1–3 μM was needed (data 
not shown). These findings are consistent with the work of Sirohi et al., who revealed 
higher response rates to platinum based therapy for TN tumours compared to other types 
of breast cancer in a retrospective study (Sirohi et al., 2008). Carboplatin was found to be 
less potent than cisplatin and lobaplatin, respectively. In case of the human TN cell lines a 
concentration of 10 μM was required to obtain a cytotoxic effect. Apparently, the highest 
effects of the drugs became obvious with HCC-1937 cells, which were shown to have the 
BRCA1 mutation (Tomlinson et al., 1998).  
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carboplatin 10 µM
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Fig. 2: In vitro treatment of various human 
breast cancer cell types with platinum drugs. 
Plots of corrected T/C values versus time 
determined in the kinetic crystal violet assay. ● 
MDA-MB-231, ■ MCF-7, □ T-47-D, ● HCC-
1806, ○ HCC-1937 
 
Additionally, the TN breast cancer cell types HCC-1806 and HCC-1937 were tested for 
their chemosensitivity against various other chemotherapeutics. With vinblastin and 
doxorubicin two classical cytostatic drugs were used. Furthermore, the classical 
antiestrogen tamoxifen and the estrogen receptor antagonist fulvestrant were used to 
demonstrate their ineffectiveness against TN cancers.  
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tamoxifen 5 µM
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Fig. 4: In vitro treatment of TN breast cancer cell types with various cytostatic drugs. Plots of 
corrected T/C values versus time, determined in the kinetic crystal violet assay. ○ HCC-1937; ●  
HCC-1806; ○ growth curve solvent control HCC-1937; ● growth curve solvent control HCC-1806 
3.2 Tumorigenicity and histology of HCC-1806 and HCC-1937 tumors 
In order to evaluate the tumorigenicity of HCC-1806 and HCC-1937, the TN breast cancer 
cells were injected into nude mice and the growth of subcutaneous xenografts was 
determined once a week. As shown in Fig. 4, both cell types were highly tumorigenic. 
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Fig. 4: In vivo growth curves of subcutaneous 
HCC-1806 (●) and HCC-1937 (■) 
xenografts. Data points are mean values ± 
SEM of 8 animals. 
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The subcutaneous solid xenografts formed by TN breast cancer cells were excised and 
characterized histologically. Both tumors showed poor differentiation, with cells 
containing prominent pleomorphic vesicular nucleoli. Typical for cancer cells there was an 
increased ratio of nucleus to cytoplasm. Furthermore, a high number of mitotic figures 
with abnormal mitotic spindles and fragments of condensed chromatin were observed. 
Both xenografts displayed a very low grade of tubule formation. In addition, the HCC-
1937 tumor exhibited necrotic areas (Fig. 5). In summary, both anaplastic tumors are 
classified as grade 3 according to the breast cancer grading criteria of Elston and Ellis 
(Elston and Ellis, 1991). 
  
  
Fig. 5: Masson-Goldner staining of subcutaneous tumors originating from HCC-1806 (left) and 
HCC-1937 (right) cells 
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4 Summary 
There is need for new anti-cancer drugs in the treatment of patients suffering from TN 
breast cancer phenotype, since no targeted therapy is available and because several studies 
have demonstrated that a poor prognosis is associated with the TN phenotype (Bauer et 
al., 2007; Sorlie et al., 2003; Tan et al., 2008). The role of platinum compounds was 
considered in TN tumors taking into account their mechanism of action and the potential 
DNA changes in these tumors, which are phenotypically and molecularly similar to 
tumors bearing the BRCA1 mutation. DNA repair defects may be adequate targets for 
alkylating agents. There are many ongoing trials in adjuvant, neoadjuvant and metastatic 
settings: carboplatin versus docetaxel (NCT00532727), gemcitabine plus cisplatin 
(NCT00601159), and gemcitabine plus oxaliplatin (NCT00674206) are some examples 
(Chacon and Costanzo, 2010).  
In this study, cytotoxic activity of the third-generation platinum drug lobaplatin against 
triple-negative breast cancer cell types was compared to the standard platinum-based 
drugs cisplatin and carboplatin. Lobaplatin proved to be as effective as cisplatin in these in 
vitro studies against TN cancer cell lines.  
In addition, the in vivo growth of TN tumors after injecting HCC-1806 and HCC-1937 
cells into nude mice was monitored. Both cell types displayed a high tumorigenicity. 
Histological investigations revealed that both the TN tumors were anaplastic and could be 
classified as tumors of the highest grade 3. 
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